1
|
Kilian M, Friedrich MJ, Lu KHN, Vonhören D, Jansky S, Michel J, Keib A, Stange S, Hackert N, Kehl N, Hahn M, Habel A, Jung S, Jähne K, Sahm F, Betge J, Cerwenka A, Westermann F, Dreger P, Raab MS, Meindl-Beinker NM, Ebert M, Bunse L, Müller-Tidow C, Schmitt M, Platten M. The immunoglobulin superfamily ligand B7H6 subjects T cell responses to NK cell surveillance. Sci Immunol 2024; 9:eadj7970. [PMID: 38701193 DOI: 10.1126/sciimmunol.adj7970] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2023] [Accepted: 03/15/2024] [Indexed: 05/05/2024]
Abstract
Understanding the mechanisms that regulate T cell immunity is critical for the development of effective therapies for diseases associated with T cell dysfunction, including autoimmune diseases, chronic infections, and cancer. Co-inhibitory "checkpoint molecules," such as programmed cell death protein-1, balance excessive or prolonged immune activation by T cell-intrinsic signaling. Here, by screening for mediators of natural killer (NK) cell recognition on T cells, we identified the immunoglobulin superfamily ligand B7H6 to be highly expressed by activated T cells, including patient-infused CD19-targeting chimeric antigen receptor (CAR) T cells. Unlike other checkpoint molecules, B7H6 mediated NKp30-dependent recognition and subsequent cytolysis of activated T cells by NK cells. B7H6+ T cells were prevalent in the tissue and blood of several diseases, and their abundance in tumor tissue positively correlated with clinical response in a cohort of patients with immune checkpoint inhibitor-treated esophageal cancer. In humanized mouse models, NK cell surveillance via B7H6 limited the persistence and antitumor activity of CAR T cells, and its genetic deletion enhanced T cell proliferation and persistence. Together, we provide evidence of B7H6 protein expression by activated T cells and suggest the B7H6-NKp30 axis as a therapeutically actionable NK cell-dependent immune checkpoint that regulates human T cell function.
Collapse
Affiliation(s)
- Michael Kilian
- DKTK Clinical Cooperation Unit (CCU) Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany
- Department of Neurology, MCTN, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
| | - Mirco J Friedrich
- Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA
- Department of Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany
| | - Kevin Hai-Ning Lu
- DKTK Clinical Cooperation Unit (CCU) Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany
- Department of Neurology, MCTN, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
- Department of Pediatric Hematology and Oncology, Clinic of Pediatrics III, University Hospital Essen, Essen, Germany
| | - David Vonhören
- Hopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany
- Division of Neuroblastoma Genomics, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Selina Jansky
- Department of Pediatric Hematology and Oncology, Clinic of Pediatrics III, University Hospital Essen, Essen, Germany
- Hopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany
| | - Julius Michel
- DKTK Clinical Cooperation Unit (CCU) Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany
- Department of Neurology, MCTN, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
| | - Anna Keib
- Department of Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany
| | - Saskia Stange
- DKTK Clinical Cooperation Unit (CCU) Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany
- Department of Neurology, MCTN, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
| | - Nicolaj Hackert
- Department of Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany
| | - Niklas Kehl
- DKTK Clinical Cooperation Unit (CCU) Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany
- Department of Neurology, MCTN, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
| | - Markus Hahn
- DKTK Clinical Cooperation Unit (CCU) Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany
- Department of Neurology, MCTN, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
| | - Antje Habel
- Department of Neuropathology, Heidelberg University Hospital, Heidelberg, Germany
| | - Stefanie Jung
- DKTK Clinical Cooperation Unit (CCU) Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany
- Department of Neurology, MCTN, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
| | - Kristine Jähne
- DKTK Clinical Cooperation Unit (CCU) Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany
- Department of Neurology, MCTN, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
| | - Felix Sahm
- Department of Neuropathology, Heidelberg University Hospital, Heidelberg, Germany
- Clinical Cooperation Unit (CCU) Neuropathology, German Consortium for Translational Cancer Research (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Johannes Betge
- Junior Clinical Cooperation Unit Translational Gastrointestinal Oncology and Preclinical Models, German Cancer Research Center (DKFZ), Heidelberg, Germany
- Department of Medicine II, University Medical Center Mannheim, Heidelberg University, Mannheim, Germany
- DKFZ-Hector Cancer Institute, University Medical Center Mannheim, Mannheim, Germany
- German Cancer Consortium (DKTK), Heidelberg, Germany
| | - Adelheid Cerwenka
- DKFZ-Hector Cancer Institute, University Medical Center Mannheim, Mannheim, Germany
- Department of Immunobiochemistry, Mannheim Institute for Innate Immunosciences (MI3), Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
| | - Frank Westermann
- Hopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany
- Division of Neuroblastoma Genomics, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Peter Dreger
- Division of Neuroblastoma Genomics, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Marc S Raab
- Department of Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany
- Clinical Cooperation Unit (CCU) Molecular Hematology/Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Nadja M Meindl-Beinker
- Department of Medicine II, University Medical Center Mannheim, Heidelberg University, Mannheim, Germany
- DKFZ-Hector Cancer Institute, University Medical Center Mannheim, Mannheim, Germany
| | - Matthias Ebert
- Department of Medicine II, University Medical Center Mannheim, Heidelberg University, Mannheim, Germany
- DKFZ-Hector Cancer Institute, University Medical Center Mannheim, Mannheim, Germany
| | - Lukas Bunse
- DKTK Clinical Cooperation Unit (CCU) Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany
- Department of Neurology, MCTN, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
| | - Carsten Müller-Tidow
- Department of Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany
| | - Michael Schmitt
- Department of Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany
| | - Michael Platten
- DKTK Clinical Cooperation Unit (CCU) Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany
- Department of Neurology, MCTN, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
- DKFZ-Hector Cancer Institute, University Medical Center Mannheim, Mannheim, Germany
- Helmholtz Institute of Translational Oncology (HI-TRON), Mainz, Germany
- Immune Monitoring Unit, National Center for Tumor Diseases (NCT), Heidelberg, Germany
| |
Collapse
|
2
|
Gal A, Gravier-Dumonceau R, Penicaud M, Ebode D, Radulesco T, Michel J. Efficacy of dupilumab in real-life settings: a STROBE study. Eur Arch Otorhinolaryngol 2024:10.1007/s00405-024-08553-9. [PMID: 38498194 DOI: 10.1007/s00405-024-08553-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2024] [Accepted: 02/12/2024] [Indexed: 03/20/2024]
Abstract
BACKGROUND Dupilumab, a monoclonal antibody targeting IL-4 and IL-13, has demonstrated its efficacy in several clinical trials. However, to date, real-life data remains limited. OBJECTIVE The aim of our study was to assess the real-life impact of dupilumab on patients with severe and uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP) quality of life. MATERIALS AND METHODS This was a retrospective, monocentric, observational, real-life study, conducted in accordance with the STROBE guidelines. The following parameters were collected before treatment and at 1, 4, and 12 months: Sino-Nasal Outcome Test-22 (SNOT-22), nasal polyp score (NPS), Sniffin' Sticks-16 (SST-16), visual analog scale (VAS) for loss of smell, nasal congestion score (NCS), gustatory VAS, asthma control, oral corticosteroid usage, surgery rates, and occurrence of side effects. RESULTS The study included 47 patients. SNOT-22 scores decreased from 52.4 ± 24.3 to 12.7 ± 10.5 at 12 months (p < 0.001). NPS decreased from 6.15 ± 1.71 to 1.57 ± 1.40 at 12 months (p < 0.001). SST-16 scores increased from 1.6 ± 2.83 to 9.1 ± 5.4 at 12 months (p < 0.001). NCS decreased from 2.45 ± 0.72 to 0.38 ± 0.63 at 12 months (p < 0.001). Prior to treatment, 72.3% were using oral corticosteroids, compared to 17.0% at 12 months (p < 0.01). Two patients required additional surgery, and 17% reported completely uncontrolled asthma, compared to 0% at 12 months (p < 0.01). CONCLUSION Our real-life results confirm the efficacy of Dupilumab in the treatment of severe and uncontrolled CRSwNP.
Collapse
Affiliation(s)
- A Gal
- APHM, La Conception University Hospital, ENT-HNS, Department, Aix Marseille Univ, Marseille, France
| | - R Gravier-Dumonceau
- APHM, INSERM, IRD, SESSTIM, Sciences Economiques & Sociales de la Santé & Traitement de l'Information Médicale, ISSPAM, Hop Timone, BioSTIC, Biostatistique et Technologies de l'Information et de La Communication, Aix Marseille Univ, Marseille, France
| | - M Penicaud
- APHM, La Conception University Hospital, ENT-HNS, Department, Aix Marseille Univ, Marseille, France
| | - D Ebode
- APHM, La Conception University Hospital, ENT-HNS, Department, Aix Marseille Univ, Marseille, France
| | - T Radulesco
- Aix Marseille Univ, APHM, CNRS, IUSTI, La Conception University Hospital, ENT-HNS, Department, Marseille, France, Aix Marseille Univ, Marseille, France.
| | - J Michel
- Aix Marseille Univ, APHM, CNRS, IUSTI, La Conception University Hospital, ENT-HNS, Department, Marseille, France, Aix Marseille Univ, Marseille, France
| |
Collapse
|
3
|
Laurenceau T, Marcou Q, Agostinucci JM, Martineau L, Metzger J, Nadiras P, Michel J, Petrovic T, Adnet F, Lapostolle F. Quantifying physician's bias to terminate resuscitation. The TERMINATOR Study. Resuscitation 2023; 188:109818. [PMID: 37150394 DOI: 10.1016/j.resuscitation.2023.109818] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/26/2022] [Revised: 04/12/2023] [Accepted: 04/27/2023] [Indexed: 05/09/2023]
Abstract
Context Deciding on "termination of resuscitation" (TOR) is a dilemma for any physician facing cardiac arrest. Due to the lack of evidence-based criteria and scarcity of the existing guidelines, crucial arbitration to interrupt resuscitation remains at the practitioner's discretion. AIM Evaluate with a quantitative method the existence of a physician internal bias to terminate resuscitation. METHOD We extracted data concerning OHCAs managed between January 2013 and September 2021 from the RéAC registry. We conducted a statistical analysis using generalized linear mixed models to model the binary TOR decision. Utstein data were used as fixed effect terms and a random effect term to model physicians personal bias towards TOR. RESULTS 5,144 OHCAs involving 173 physicians were included. The cohort's average age was 69 (SD 18) and was composed of 62% of women. Median no-flow and low-flow times were respectively 6 (IQR [0,12]) and 18 (IQR [10,26]) minutes. Our analysis showed a significant (p<0.001) physician effect on TOR decision. Odds ratio for the "doctor effect" was 2.48 [2.13-2.94] for a doctor one SD above the mean, lower than that of dependency for activities of daily living (41.18 [24.69-65.50]), an age of more than 85 years (38.60 [28.67-51.08]), but higher than that of oncologic, cardiovascular, respiratory disease or no-flow duration between 10 to 20 minutes (1.60 [1.26-2.00]). CONCLUSIONS We demonstrate the existence of individual physician biases in their decision about TOR. The impact of this bias is greater than that of a no-flow duration lasting ten to twenty minutes. Our results plead in favor developing tools and guidelines to guide physicians in their decision.
Collapse
Affiliation(s)
- T Laurenceau
- SAMU 93, UF Recherche-Enseignement-Qualité, Université Paris 13, Sorbonne Paris Cité, Inserm U942. Hôpital Avicenne, APHP, 125, rue de Stalingrad, 93009 Bobigny, France.
| | - Q Marcou
- Faculté des Sciences Médicales et Paramédicales, Aix-Marseille Université, 27 boulevard Jean Moulin, 13005, Marseille, France.
| | - J M Agostinucci
- SAMU 93, UF Recherche-Enseignement-Qualité, Université Paris 13, Sorbonne Paris Cité, Inserm U942. Hôpital Avicenne, APHP, 125, rue de Stalingrad, 93009 Bobigny, France.
| | - L Martineau
- SMUR, Urgences Centre hospitalier intercommunal Robert Ballanger, Boulevard Robert Ballanger, 93600 Aulnay-sous-Bois, France.
| | - J Metzger
- SAMU 93, UF Recherche-Enseignement-Qualité, Université Paris 13, Sorbonne Paris Cité, Inserm U942. Hôpital Avicenne, APHP, 125, rue de Stalingrad, 93009 Bobigny, France.
| | - P Nadiras
- SMUR Groupe hospitalier intercommunal Le Raincy-Montfermeil, 10, rue du Général Leclerc, 93370 Montfermeil, France.
| | - J Michel
- SAMU 93, UF Recherche-Enseignement-Qualité, Université Paris 13, Sorbonne Paris Cité, Inserm U942. Hôpital Avicenne, APHP, 125, rue de Stalingrad, 93009 Bobigny, France.
| | - T Petrovic
- SAMU 93, UF Recherche-Enseignement-Qualité, Université Paris 13, Sorbonne Paris Cité, Inserm U942. Hôpital Avicenne, APHP, 125, rue de Stalingrad, 93009 Bobigny, France.
| | - F Adnet
- SAMU 93, UF Recherche-Enseignement-Qualité, Université Paris 13, Sorbonne Paris Cité, Inserm U942. Hôpital Avicenne, APHP, 125, rue de Stalingrad, 93009 Bobigny, France.
| | - F Lapostolle
- SAMU 93, UF Recherche-Enseignement-Qualité, Université Paris 13, Sorbonne Paris Cité, Inserm U942. Hôpital Avicenne, APHP, 125, rue de Stalingrad, 93009 Bobigny, France.
| |
Collapse
|
4
|
Friedrich MJ, Neri P, Kehl N, Michel J, Steiger S, Kilian M, Leblay N, Maity R, Sankowski R, Lee H, Barakat E, Ahn S, Weinhold N, Rippe K, Bunse L, Platten M, Goldschmidt H, Müller-Tidow C, Raab MS, Bahlis NJ. The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients. Cancer Cell 2023; 41:711-725.e6. [PMID: 36898378 DOI: 10.1016/j.ccell.2023.02.008] [Citation(s) in RCA: 36] [Impact Index Per Article: 36.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/20/2022] [Revised: 11/02/2022] [Accepted: 02/08/2023] [Indexed: 03/11/2023]
Abstract
Bispecific T cell engagers (TCEs) have shown promise in the treatment of various cancers, but the immunological mechanism and molecular determinants of primary and acquired resistance to TCEs remain poorly understood. Here, we identify conserved behaviors of bone marrow-residing T cells in multiple myeloma patients undergoing BCMAxCD3 TCE therapy. We show that the immune repertoire reacts to TCE therapy with cell state-dependent clonal expansion and find evidence supporting the coupling of tumor recognition via major histocompatibility complex class I (MHC class I), exhaustion, and clinical response. We find the abundance of exhausted-like CD8+ T cell clones to be associated with clinical response failure, and we describe loss of target epitope and MHC class I as tumor-intrinsic adaptations to TCEs. These findings advance our understanding of the in vivo mechanism of TCE treatment in humans and provide the rationale for predictive immune-monitoring and conditioning of the immune repertoire to guide future immunotherapy in hematological malignancies.
Collapse
Affiliation(s)
- Mirco J Friedrich
- Department of Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
| | - Paola Neri
- Arnie Charbonneau Cancer Research Institute, University of Calgary, Calgary, Canada; Tom Baker Cancer Center, Department of Hematology and Oncology, Calgary, Canada
| | - Niklas Kehl
- Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany; Department of Neurology, MCTN, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
| | - Julius Michel
- Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany; Department of Neurology, MCTN, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
| | - Simon Steiger
- Division of Chromatin Networks, BioQuant Center & German Cancer Research Center (DKFZ), Heidelberg, Germany; Faculty of Biosciences, Heidelberg University, Heidelberg, Germany
| | - Michael Kilian
- Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany; Department of Neurology, MCTN, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
| | - Noémie Leblay
- Tom Baker Cancer Center, Department of Hematology and Oncology, Calgary, Canada
| | - Ranjan Maity
- Tom Baker Cancer Center, Department of Hematology and Oncology, Calgary, Canada
| | - Roman Sankowski
- Department of Neuropathology, Freiburg University Hospital, Freiburg, Germany
| | - Holly Lee
- Arnie Charbonneau Cancer Research Institute, University of Calgary, Calgary, Canada; Tom Baker Cancer Center, Department of Hematology and Oncology, Calgary, Canada
| | - Elie Barakat
- Tom Baker Cancer Center, Department of Hematology and Oncology, Calgary, Canada
| | - Sungwoo Ahn
- Tom Baker Cancer Center, Department of Hematology and Oncology, Calgary, Canada
| | - Niels Weinhold
- Department of Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany
| | - Karsten Rippe
- Division of Chromatin Networks, BioQuant Center & German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Lukas Bunse
- Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany; Department of Neurology, MCTN, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
| | - Michael Platten
- Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany; Department of Neurology, MCTN, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany; Helmholtz Institute of Translational Oncology (HI-TRON), Mainz, Germany; National Center for Tumor Diseases (NCT), Heidelberg, Germany; DKFZ Hector Cancer Institute at the University Medical Center Mannheim, Mannheim Germany
| | - Hartmut Goldschmidt
- Department of Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany; National Center for Tumor Diseases (NCT), Heidelberg, Germany
| | - Carsten Müller-Tidow
- Department of Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany; National Center for Tumor Diseases (NCT), Heidelberg, Germany
| | - Marc-Steffen Raab
- Department of Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany; Clinical Cooperation Unit Molecular Hematology/Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
| | - Nizar J Bahlis
- Arnie Charbonneau Cancer Research Institute, University of Calgary, Calgary, Canada; Tom Baker Cancer Center, Department of Hematology and Oncology, Calgary, Canada.
| |
Collapse
|
5
|
Almouallem W, Michel J, Dorge S, Joyeux C, Trouvé G, Le Nouen D. A comparative study of the sorption of O-PAHs and PAHs onto soils to understand their transport in soils and groundwater. J Environ Sci (China) 2023; 124:61-75. [PMID: 36182167 DOI: 10.1016/j.jes.2021.11.001] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2021] [Revised: 10/29/2021] [Accepted: 11/01/2021] [Indexed: 06/16/2023]
Abstract
Polycyclic aromatic hydrocarbons (PAHs) and their oxygenated derivates (O-PAHs) are identified in soils and groundwater of industrialized sites and contribute to the risk for Humans and the Environment. Nevertheless, data are scarce in literature concerning their retention and transfer in soils and no soil - water partition coefficients are available for these compounds. Sorption of two PAHs, fluorene and acenaphthene and two O-PAHs, 9H-fluorenone and dibenzofuran onto two soils with different organic carbon contents was evaluated and compared by determining their sorption isotherms. Effect of ionic strength and liquid to solid ratio, on fluorene and fluorenone sorption was also evaluated. Sorption equilibrium is achieved within less than 24 hr of mixing and linear sorption models best fit the isotherm data. Acenaphthene and dibenzofuran are similarly sorbed onto the soil. KD of fluorene is higher than the one of fluorenone, showing a smaller affinity of fluorenone towards the solid phase. This means that O-PAH could form larger contamination plumes in groundwater than PAHs. Decreasing the L/S ratio from 100 to 50 and 30, increases the sorption of fluorenone onto the soil by 56% and 67% respectively, while the sorption of fluorene is slightly increased. Increasing the ionic strength of the aqueous phase also modifies the sorption of fluorenone, contrary to the sorption of fluorene which is slightly affected.
Collapse
Affiliation(s)
- W Almouallem
- French National Institute for Industrial and Environment and Risks, Direction Sites & Territoires, Verneuil en Halatte, F-60550, France; University of Haute-Alsace, Laboratoire Gestion des Risques et Environnement (LGRE) UR2334, Mulhouse, France; University of Strasbourg, 67000 Strasbourg, France; University of Haute-Alsace, Laboratoire d'Innovation Moléculaire et Applications (LIMA) UMR 7042 CNRS, Mulhouse, France
| | - J Michel
- French National Institute for Industrial and Environment and Risks, Direction Sites & Territoires, Verneuil en Halatte, F-60550, France
| | - S Dorge
- University of Haute-Alsace, Laboratoire Gestion des Risques et Environnement (LGRE) UR2334, Mulhouse, France; University of Strasbourg, 67000 Strasbourg, France
| | - C Joyeux
- University of Strasbourg, 67000 Strasbourg, France; University of Haute-Alsace, Laboratoire d'Innovation Moléculaire et Applications (LIMA) UMR 7042 CNRS, Mulhouse, France
| | - G Trouvé
- University of Haute-Alsace, Laboratoire Gestion des Risques et Environnement (LGRE) UR2334, Mulhouse, France; University of Strasbourg, 67000 Strasbourg, France.
| | - D Le Nouen
- University of Strasbourg, 67000 Strasbourg, France; University of Haute-Alsace, Laboratoire d'Innovation Moléculaire et Applications (LIMA) UMR 7042 CNRS, Mulhouse, France
| |
Collapse
|
6
|
Grigioni S, Lvovschi VE, Tamion F, Joly LM, Coëffier M, Van Elslande H, Galmiche M, Gâté M, Traore-Ouattara U, Marais B, Michel J, Dechelotte P, Savoye-Collet C, Achamrah N. Low thoracic skeletal muscle index is associated with negative outcomes in 244 patients with respiratory COVID-19. Clin Nutr 2023; 42:102-107. [PMID: 36521254 PMCID: PMC9674398 DOI: 10.1016/j.clnu.2022.11.011] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2022] [Revised: 10/27/2022] [Accepted: 11/09/2022] [Indexed: 11/20/2022]
Abstract
BACKGROUND Sarcopenia is associated with negative outcomes in intensive care unit (ICU) patients and during chronic diseases. We aimed to evaluate if low skeletal muscle index (SMI) measured by computed tomography (CT) at the thoracic level is associated with poor outcomes in hospitalized patients with respiratory COVID-19. METHODS Patients admitted to the hospital between March 1st and June 9, 2020 with a confirmed diagnosis of respiratory COVID-19 in the Emergency Department were included in this retrospective cohort study. SMI was assessed from a transverse CT image at the T12 level. We analysed the association between thoracic SMI and mortality, ICU admissions, infections, length of stay and gravity scores. RESULTS We included 244 patients, whose median age was 62 (20-95) years, mean body mass index was 28,6 kg/m2, and 34% were obese patients. 102 patients (41,8%) had low thoracic SMI. On multivariable analysis, low thoracic SMI was associated with more infections (OR = 1,88 [1,06-2,98]) and increased length of stay (OR = 1,87 [1,14-3,49]) but not with mortality (OR = 1.37 [0.54-3.52]), whereas it was inversely associated with ICU admission (OR = 5,56 [1,96-16,67]. CONCLUSION Low SMI measured by CT at the thoracic level T12 is associated with negative outcomes in patients with respiratory COVID-19.
Collapse
Affiliation(s)
- S Grigioni
- Nutrition Department, CHU Rouen, Rouen, France; Normandie Univ, UNIROUEN, INSERM UMR 1073, Nutrition, Inflammation et axe microbiote-intestin-cerveau, IRIB, Rouen, France; Clinical Investigation Centre CIC 1404, INSERM and CHU Rouen, France
| | - V-E Lvovschi
- Normandie Univ, UNIROUEN, INSERM UMR 1073, Nutrition, Inflammation et axe microbiote-intestin-cerveau, IRIB, Rouen, France; Emergency Department, CHU Rouen, Rouen, France
| | - F Tamion
- Medical Intensive Care Unit, CHU Rouen, France; Normandie Univ, UNIROUEN, INSERM U1096, F-76000 Rouen, France
| | - L-M Joly
- Emergency Department, CHU Rouen, Rouen, France
| | - M Coëffier
- Nutrition Department, CHU Rouen, Rouen, France; Normandie Univ, UNIROUEN, INSERM UMR 1073, Nutrition, Inflammation et axe microbiote-intestin-cerveau, IRIB, Rouen, France; Clinical Investigation Centre CIC 1404, INSERM and CHU Rouen, France
| | - H Van Elslande
- Nutrition Department, CHU Rouen, Rouen, France; Normandie Univ, UNIROUEN, INSERM UMR 1073, Nutrition, Inflammation et axe microbiote-intestin-cerveau, IRIB, Rouen, France; Clinical Investigation Centre CIC 1404, INSERM and CHU Rouen, France
| | | | - M Gâté
- Nutrition Department, CHU Rouen, Rouen, France
| | | | - B Marais
- Medical Intensive Care Unit, CHU Rouen, France
| | - J Michel
- Emergency Department, CHU Rouen, Rouen, France
| | - P Dechelotte
- Nutrition Department, CHU Rouen, Rouen, France; Normandie Univ, UNIROUEN, INSERM UMR 1073, Nutrition, Inflammation et axe microbiote-intestin-cerveau, IRIB, Rouen, France; Clinical Investigation Centre CIC 1404, INSERM and CHU Rouen, France
| | | | - N Achamrah
- Nutrition Department, CHU Rouen, Rouen, France; Normandie Univ, UNIROUEN, INSERM UMR 1073, Nutrition, Inflammation et axe microbiote-intestin-cerveau, IRIB, Rouen, France; Clinical Investigation Centre CIC 1404, INSERM and CHU Rouen, France.
| |
Collapse
|
7
|
Kehl N, Kilian M, Michel J, Wagner TR, Uhrig S, Brobeil A, Sester LS, Blobner S, Steiger S, Hundemer M, Weinhold N, Rippe K, Fröhling S, Eichmüller SB, Bunse L, Müller-Tidow C, Goldschmidt H, Platten M, Raab MS, Friedrich MJ. IgE type multiple myeloma exhibits hypermutated phenotype and tumor reactive T cells. J Immunother Cancer 2022; 10:jitc-2022-005815. [PMID: 36252999 PMCID: PMC9577923 DOI: 10.1136/jitc-2022-005815] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 09/26/2022] [Indexed: 11/04/2022] Open
Abstract
Multiple myeloma (MM) is a hematological malignancy originating from malignant and clonally expanding plasma cells. MM can be molecularly stratified, and its clonal evolution deciphered based on the Ig heavy and light chains of the respective malignant plasma cell clone. Of all MM subtypes, IgE type MM accounts for only <0.1% of cases and is associated with an aggressive clinical course and consequentially dismal prognosis. In such malignancies, adoptive transfer of autologous lymphocytes specifically targeting presented (neo)epitopes encoded by either somatically mutated or specifically overexpressed genes has resulted in substantial objective clinical regressions even in relapsed/refractory disease. However, there are no data on the genetic and immunological characteristics of this rare and aggressive entity. Here, we comprehensively profiled IgE type kappa MM on a genomic and immune repertoire level by integrating DNA- and single-cell RNA sequencing and comparative profiling against non-IgE type MM samples. We demonstrate distinct pathophysiological mechanisms as well as novel opportunities for targeting IgE type MM. Our data further provides the rationale for patient-individualized neoepitope-targeting cell therapy in high tumor mutation burden MM.
Collapse
Affiliation(s)
- Niklas Kehl
- Department of Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany,Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany,Department of Neurology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
| | - Michael Kilian
- Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany,Department of Neurology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
| | - Julius Michel
- Department of Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany,Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany,Department of Neurology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
| | - Tim R Wagner
- Department of Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany,GMP and Cell Therapy Group, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Sebastian Uhrig
- Molecular Precision Oncology Program, National Center for Tumor Diseases, Heidelberg, Germany
| | - Alexander Brobeil
- Department of Pathology, University Hospital Heidelberg, Heidelberg, Germany
| | - Lilli-Sophie Sester
- Department of Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany
| | - Sven Blobner
- Department of Translational Oncology, National Center of Tumor Diseases (NCT) and German Cancer Consortium (DKTK), Heidelberg, Germany
| | - Simon Steiger
- Division of Chromatin Networks, BioQuant Center and German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Michael Hundemer
- Department of Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany
| | - Niels Weinhold
- Department of Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany
| | - Karsten Rippe
- Division of Chromatin Networks, BioQuant Center and German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Stefan Fröhling
- Department of Translational Oncology, National Center of Tumor Diseases (NCT) and German Cancer Consortium (DKTK), Heidelberg, Germany
| | - Stefan B Eichmüller
- GMP and Cell Therapy Group, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Lukas Bunse
- Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany,Department of Neurology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
| | - Carsten Müller-Tidow
- Department of Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany
| | - Hartmut Goldschmidt
- Department of Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany,National Center of Tumor Diseases (NCT) and German Cancer Consortium (DKTK), Heidelberg, Germany
| | - Michael Platten
- Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany,Department of Neurology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany,National Center of Tumor Diseases (NCT) and German Cancer Consortium (DKTK), Heidelberg, Germany,DKFZ Hector Cancer Institute at the University Medical Center Mannheim, Mannheim, Germany
| | - Marc-Steffen Raab
- Department of Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany,Clinical Cooperation Unit Molecular Hematology / Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Mirco J Friedrich
- Department of Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany,Faculty of Biosciences, Heidelberg University, Heidelberg, Germany
| |
Collapse
|
8
|
Lu KHN, Michel J, Kilian M, Aslan K, Qi H, Kehl N, Jung S, Sanghvi K, Lindner K, Zhang XW, Green EW, Poschke I, Ratliff M, Bunse T, Sahm F, von Deimling A, Wick W, Platten M, Bunse L. T cell receptor dynamic and transcriptional determinants of T cell expansion in glioma-infiltrating T cells. Neurooncol Adv 2022; 4:vdac140. [PMID: 36196364 PMCID: PMC9526356 DOI: 10.1093/noajnl/vdac140] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
Abstract
Background Glioblastoma (GBM) is characterized by low numbers of glioma-infiltrating lymphocytes (GIL) with a dysfunctional phenotype. Whether this dysfunctional phenotype is fixed or can be reversed upon ex vivo culturing is poorly understood. The aim of this study was to assess T cell receptor (TCR)-dynamics and -specificities as well as determinants of in vitro GIL expansion by sequencing-based technologies and functional assays to explore the use of GIL for cell therapy. Methods By means of flow cytometry, T cell functionality in GIL cultures was assessed from 9 GBM patients. TCR beta sequencing (TCRB-seq) was used for TCR repertoire profiling before and after in vitro expansion. Microarrays or RNA sequencing (RNA-seq) were performed from 6 micro-dissected GBM tissues and healthy brain RNA to assess the individual expression of GBM-associated antigens (GAA). GIL reactivity against in silico predicted tumor-associated antigens (TAA) and patient-individual GAA was assessed by ELISpot assay. Combined ex vivo single cell (sc)TCR-/RNA-seq and post-expansion TCRB-seq were used to evaluate transcriptional signatures that determine GIL expansion. Results Human GIL regains cellular fitness upon in vitro expansion. Profound TCR dynamics were observed during in vitro expansion and only in one of six GIL cultures, reactivity against GAA was observed. Paired ex vivo scTCR/RNA-seq and TCRB-seq revealed predictive transcriptional signatures that determine GIL expansion. Conclusions Profound TCR repertoire dynamics occur during GIL expansion. Ex vivo transcriptional T cell states determine expansion capacity in gliomas. Our observation has important implications for the use of GIL for cell therapy including genetic manipulation to maintain both antigen specificity and expansion capacity.
Collapse
Affiliation(s)
- Kevin Hai-Ning Lu
- DKTK Clinical Cooperation Unit (CCU) Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ) , Heidelberg, Germany
- Department of Neurology, MCTN, Medical Faculty Mannheim , Heidelberg University, Mannheim, Germany
- Department of Pediatric Hematology and Oncology, Clinic of Pediatrics III, University Hospital Essen , Essen, Germany
| | - Julius Michel
- DKTK Clinical Cooperation Unit (CCU) Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ) , Heidelberg, Germany
- Department of Neurology, MCTN, Medical Faculty Mannheim , Heidelberg University, Mannheim, Germany
| | - Michael Kilian
- DKTK Clinical Cooperation Unit (CCU) Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ) , Heidelberg, Germany
- Department of Neurology, MCTN, Medical Faculty Mannheim , Heidelberg University, Mannheim, Germany
| | - Katrin Aslan
- DKTK Clinical Cooperation Unit (CCU) Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ) , Heidelberg, Germany
- Department of Neurology, MCTN, Medical Faculty Mannheim , Heidelberg University, Mannheim, Germany
| | - Hao Qi
- DKTK Clinical Cooperation Unit (CCU) Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ) , Heidelberg, Germany
- Department of Neurology, MCTN, Medical Faculty Mannheim , Heidelberg University, Mannheim, Germany
| | - Niklas Kehl
- DKTK Clinical Cooperation Unit (CCU) Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ) , Heidelberg, Germany
- Department of Neurology, MCTN, Medical Faculty Mannheim , Heidelberg University, Mannheim, Germany
| | - Stefanie Jung
- DKTK Clinical Cooperation Unit (CCU) Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ) , Heidelberg, Germany
- Department of Neurology, MCTN, Medical Faculty Mannheim , Heidelberg University, Mannheim, Germany
| | - Khwab Sanghvi
- DKTK Clinical Cooperation Unit (CCU) Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ) , Heidelberg, Germany
- Department of Neurology, MCTN, Medical Faculty Mannheim , Heidelberg University, Mannheim, Germany
| | - Katharina Lindner
- DKTK Clinical Cooperation Unit (CCU) Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ) , Heidelberg, Germany
- Department of Pediatric Hematology and Oncology, Clinic of Pediatrics III, University Hospital Essen , Essen, Germany
- Immune Monitoring Unit, National Center for Tumor Diseases (NCT) , Heidelberg, Germany
| | - Xin-Wen Zhang
- DKTK Clinical Cooperation Unit (CCU) Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ) , Heidelberg, Germany
- Department of Neurology, MCTN, Medical Faculty Mannheim , Heidelberg University, Mannheim, Germany
- Medical Oncology and Internal Medicine VI, National Center for Tumor Diseases (NCT), University Hospital Heidelberg , 69120 Heidelberg, Germany
| | - Edward W Green
- DKTK Clinical Cooperation Unit (CCU) Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ) , Heidelberg, Germany
- Department of Neurology, MCTN, Medical Faculty Mannheim , Heidelberg University, Mannheim, Germany
| | - Isabel Poschke
- Immune Monitoring Unit, National Center for Tumor Diseases (NCT) , Heidelberg, Germany
| | - Miriam Ratliff
- Department of Neurosurgery, University Hospital Mannheim , Mannheim, Germany
| | - Theresa Bunse
- DKTK Clinical Cooperation Unit (CCU) Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ) , Heidelberg, Germany
- Department of Neurology, MCTN, Medical Faculty Mannheim , Heidelberg University, Mannheim, Germany
| | - Felix Sahm
- Department of Neuropathology, Heidelberg University Medical Center , Heidelberg, Germany
- CCU Neuropathology, DKFZ, DKTK , Heidelberg, Germany
| | - Andreas von Deimling
- Department of Neuropathology, Heidelberg University Medical Center , Heidelberg, Germany
- CCU Neuropathology, DKFZ, DKTK , Heidelberg, Germany
| | - Wolfgang Wick
- Department of Neurology, University Clinic Heidelberg, Heidelberg University , Heidelberg, Germany
- DKTK CCU Neurooncology, German Cancer Research Center (DKFZ) , Heidelberg, Germany
| | - Michael Platten
- DKTK Clinical Cooperation Unit (CCU) Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ) , Heidelberg, Germany
- Department of Neurology, MCTN, Medical Faculty Mannheim , Heidelberg University, Mannheim, Germany
- Immune Monitoring Unit, National Center for Tumor Diseases (NCT) , Heidelberg, Germany
- Helmholtz Institute of Translational Oncology (HI-TRON) , Mainz, Germany
- DKFZ Hector Cancer Institute at the University Medical Center Mannheim , Mannheim Germany
| | - Lukas Bunse
- DKTK Clinical Cooperation Unit (CCU) Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ) , Heidelberg, Germany
- Department of Neurology, MCTN, Medical Faculty Mannheim , Heidelberg University, Mannheim, Germany
| |
Collapse
|
9
|
Greca E, Kacimi SEO, Ghozy S, Wireko AA, Toufik A, Poudel S, Prendi B, Michel G, Michel J. Immunomodulatory effect of different statin regimens on regulatory T-cells among patients with acute coronary syndrome: a systematic review and network meta-analysis of randomized clinical trials. Cardiovasc Res 2022. [DOI: 10.1093/cvr/cvac066.148] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Funding Acknowledgements
Type of funding sources: None.
Immunomodulatory effect of different statin regimens on regulatory T-cells among patients with acute coronary syndrome: a systematic review and network meta-analysis of randomized clinical trials
Introduction
In patients with acute coronary syndrome (ACS), studies suggest that statin therapy, besides its role in reducing the progression of atherosclerosis through its pharmacological effect, plays a pivotal role in controlling the pathogenesis of ACS through the anti-inflammatory effects of suppressor regulatory T cells (Tregs).
Purpose
We conducted a network meta-analysis (NMA) to determine the effects of low-dose conventional statin therapy (CST) (20 mg/day or less) and high-dose intensive statin therapy (IST) (40 mg/day or more) on the frequency of Tregs and their associated cytokines (IFN-γ, IL-10, TGF-β), compared to placebo.
Methods
The PubMed, Cochrane Library, and EMBASE databases were searched for randomized clinical trials (RCTs) to identify relevant articles published until June 2021. We pooled data extracted from the included studies using the standardized mean difference (SMD). A random-effects model was used to conduct this NMA. Heterogeneity was evaluated using Cochran's Q- and the I2-test. GRADE(Grading of Recommendations, Assessment, Development and Evaluations) was used to assess the study's quality. Data analysis was conducted using R software.
Results
A total of 505 patients were enrolled in the 5 RCTs. The NMA indicated a significant increase in Treg frequency in the CST group compared with the control group (SMD 1.77; 95% CI: 0.77 – 2.76; P-value = 0.0005) and a larger increase in the Treg frequency associated with the IST group compared with the control group (SMD 2.12; 95% CI: 1.15 – 3.10; P-value < 0.0001). However, there was significant heterogeneity and inconsistency among the included studies (τ2 = 0.6096; τ = 0.7808; I2 = 91.2% [80.5%; 96.0%]). When compared to the placebo, both CST and IST increased levels of secreted IL-10 (SMD 2.69; 95% CI: 2.07 – 3.31; P-value < 0.0001 and (SMD 2.14; 95% CI: 1.76 – 2.52; P-value < 0.0001), respectively. In comparison to the control group, CST was associated with increased levels of TGF-β (SMD 3.83; 95% CI: 0.63 – 7.0; P-value = 0.0189). This association was not seen in the IST group. IFN-γ levels decreased significantly in both the IST and CST groups (SMD -1.52; 95% CI: -1.94 – -1.10; P-value < 0.0001) and (SMD -2.34; 95% CI: -2.73 – -1.95; P-value < 0.0001) respectively.
Conclusions
Our study suggests that both high and low dose statin groups showed increased Treg frequency compared to the placebo group. IST showed larger benefits. Statin therapy also increased IL-10 and TGF-β cytokine levels and decreased IFN-γ levels. Therefore, statins have the potential to be the main treatment to reduce the incidence of cardiovascular events and improve cardiac function in patients with ACS through immunomodulatory effect on Treg.
Collapse
Affiliation(s)
- E Greca
- Larkin Community Hospital, Division of Research and Academic Affairs , Miami , United States of America
| | - S E O Kacimi
- Larkin Community Hospital, Division of Research and Academic Affairs , Miami , United States of America
| | - S Ghozy
- Mayo Clinic, Department of Radiology , Rochester , United States of America
| | - A A Wireko
- Sumy State University, Medical Institute , Sumy , Ukraine
| | - A Toufik
- Sumy State University, Medical Institute , Sumy , Ukraine
| | - S Poudel
- Larkin Community Hospital, Division of Research and Academic Affairs , Miami , United States of America
| | - B Prendi
- University Hospital Center Mother Theresa , Tirana , Albania
| | - G Michel
- Larkin Community Hospital, Program Director of Internal Medicine , Miami , United States of America
| | - J Michel
- Larkin Community Hospital, Founder Larkin Health System/Larkin University , Miami , United States of America
| |
Collapse
|
10
|
Friedrich M, Hahn M, Michel J, Sankowski R, Kilian M, Kehl N, Günter M, Bunse T, Pusch S, von Deimling A, Wick W, Autenrieth SE, Prinz M, Platten M, Bunse L. Dysfunctional dendritic cells limit antigen-specific T cell response in glioma. Neuro Oncol 2022; 25:263-276. [PMID: 35609569 PMCID: PMC9925697 DOI: 10.1093/neuonc/noac138] [Citation(s) in RCA: 23] [Impact Index Per Article: 11.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2021] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND Dendritic cells (DC), the most potent professional antigen presenting cells capable of effective cross-presentation, have been demonstrated to license T helper cells to induce antitumor immunity in solid tumors. Specific DC subtypes are recruited to the injured brain by microglial chemokines, locally adapting to distinct transcriptional profiles. In isocitrate dehydrogenase (IDH) type 1 mutant gliomas, monocyte-derived macrophages have recently been shown to display an attenuated intratumoral antigen presentation capacity as consequence of the local accumulation of the oncometabolite R-2-hydroxyglutarate. The functionality and the contribution of DC to the IDH-mutant tumor microenvironment (TME) remains unclear. METHODS Frequencies and intratumoral phenotypes of human DC in IDH-wildtype (IDHwt) and -mutant high-grade gliomas are comparatively assessed by transcriptomic and proteomic profiling. DC functionality is investigated in experimental murine glioblastomas expressing the model antigen ovalbumin. Single-cell sequencing-based pseudotime analyses and spectral flow cytometric analyses are used to profile DC states longitudinally. RESULTS DC are present in primary and recurrent high-grade gliomas and interact with other immune cell types within the TME. In murine glioblastomas, we find an IDH-status-associated major histocompatibility class I-restricted cross-presentation of tumor antigens by DC specifically in the tumor but not in meninges or secondary lymphoid organs of tumor-bearing animals. In single-cell sequencing-based pseudotime and longitudinal spectral flow cytometric analyses, we demonstrate an IDH-status-dependent differential, exclusively microenvironmental education of DC. CONCLUSIONS Glioma-associated DCs are relevantly abundant in human IDHwt and mutant tumors. Glioma IDH mutations result in specifically educated, dysfunctional DCs via paracrine reprogramming of infiltrating monocytes, providing the basis for combinatorial immunotherapy concepts against IDH mutant gliomas.
Collapse
Affiliation(s)
- Mirco Friedrich
- DKTK Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany,Department of Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany,Faculty of Biosciences, Heidelberg University, Heidelberg, Germany
| | - Markus Hahn
- DKTK Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany,Department of Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany,Faculty of Biosciences, Heidelberg University, Heidelberg, Germany,Department of Neurology, MCTN, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
| | - Julius Michel
- DKTK Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany,Department of Neurology, MCTN, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
| | - Roman Sankowski
- Department of Neuropathology, Freiburg University Hospital, Freiburg, Germany
| | - Michael Kilian
- DKTK Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany,Department of Neurology, MCTN, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
| | - Niklas Kehl
- DKTK Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany,Department of Neurology, MCTN, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
| | - Manina Günter
- Dendritic Cells in Infection and Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Theresa Bunse
- DKTK Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany,Department of Neurology, MCTN, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
| | - Stefan Pusch
- Department of Neuropathology, Heidelberg University Hospital, Heidelberg, Germany,DKTK Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Andreas von Deimling
- Department of Neuropathology, Heidelberg University Hospital, Heidelberg, Germany,DKTK Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Wolfgang Wick
- Department of Neurology, Heidelberg University Hospital, Heidelberg, Germany,DKTK Clinical Cooperation Unit Neurooncology, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Stella E Autenrieth
- Dendritic Cells in Infection and Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Marco Prinz
- Department of Neuropathology, Freiburg University Hospital, Freiburg, Germany
| | - Michael Platten
- DKTK Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany,Department of Neurology, MCTN, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany,Helmholtz Institute of Translational Oncology (HI-TRON), Mainz, Germany,Immune Monitoring Unit, National Center for Tumor Diseases (NCT), Heidelberg, Germany ,DKFZ Hector Cancer Institute at the University Medical Center Mannheim, Mannheim, Germany
| | - Lukas Bunse
- Corresponding Author: Lukas Bunse, MD, PhD, German Cancer Research Center (DKFZ), Heidelberg, Germany ()
| |
Collapse
|
11
|
Sieverding L, Grözinger G, Sturm E, Hartleif S, Warmann S, Icheva V, Hofbeck M, Michel J. Interventional Removal of Large Catheter-Associated Thrombi Using a Self-Expanding Nitinol Basket. Thorac Cardiovasc Surg 2022. [DOI: 10.1055/s-0042-1742974] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Affiliation(s)
- L. Sieverding
- Department of Pediatric Cardiology, Childrens Hospital, University of Tuebingen, Tuebingen, Deutschland
| | - G. Grözinger
- Department of Diagnostic and Interventional Radiology, Frankfurt am Main, Deutschland
| | - E. Sturm
- Childrens Hospital tuebingen, Tübingen, Germany, Deutschland
| | - S. Hartleif
- Department of Pediatric Cardiology, University of Tuebingen, Tuebingen, Deutschland
| | - S. Warmann
- Kinderchirurgie, Uni-Kinderklinik Tübingen, Tübingen, Deutschland
| | - V. Icheva
- Universtiy Childrens' Hospital Tübingen, Tübingen, Deutschland
| | - M. Hofbeck
- Hoppe-Seyler-Str. 1, Tübingen, Deutschland
| | - J. Michel
- Department of Pediatric Cardiology, Childrens Hospital, University of Tuebingen, Tuebingen, Deutschland
| |
Collapse
|
12
|
Hanser A, Hornung A, Martirosian P, Esser M, Hofmeister M, Hofbeck M, Schick F, Kaulitz R, Michel J, Schäfer J, Nikolaou K, Schlensak C, Sieverding L. T2-Weighted MRI following TCPC: Fontan Patients with Type-4 Classification of the Thoracic Lymphatic Channels Show a Lower Exercise Capacity. Thorac Cardiovasc Surg 2022. [DOI: 10.1055/s-0042-1743001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Affiliation(s)
- A. Hanser
- Department of Pediatric Cardiology, University Children's Hospital, University of Tübingen, Tübingen, Deutschland
| | - A. Hornung
- Department of Pediatric Cardiology, University Children's Hospital, University of Tübingen, Tübingen, Deutschland
| | - P. Martirosian
- Section on Experimental Radiology, University Hospital of Tübingen, Tübingen, Deutschland
| | - M. Esser
- Department of Diagnostic and Interventional Radiology, University Hospital of Tübingen, Tübingen, Deutschland
| | - M. Hofmeister
- Department of Pediatric Cardiology, University Children's Hospital, University of Tübingen, Tübingen, Deutschland
| | - M. Hofbeck
- Department of Pediatric Cardiology, University Children's Hospital, University of Tübingen, Tübingen, Deutschland
| | - F. Schick
- Section on Experimental Radiology, University Hospital of Tübingen, Tübingen, Deutschland
| | - R. Kaulitz
- Department of Pediatric Cardiology, University Children's Hospital, University of Tübingen, Tübingen, Deutschland
| | - J. Michel
- Department of Pediatric Cardiology, University Children's Hospital, University of Tübingen, Tübingen, Deutschland
| | - J. Schäfer
- Department of Diagnostic and Interventional Radiology, University Hospital of Tübingen, Tübingen, Deutschland
| | - K. Nikolaou
- Department of Diagnostic and Interventional Radiology, University Hospital of Tübingen, Tübingen, Deutschland
| | - C. Schlensak
- Department of Thoracic, Cardiac, and Vascular Surgery, University Hospital of Tübingen, Tübingen, Deutschland
| | - L. Sieverding
- Department of Pediatric Cardiology, University Children's Hospital, University of Tübingen, Tübingen, Deutschland
| |
Collapse
|
13
|
Icheva V, Ebert J, Budde U, Wiegand G, Schober S, Engel J, Kumpf M, Jaschonek K, Neunhoeffer F, Michel J, Schlensak C, Hofbeck M, Magunia H. Acquired von Willebrand's Syndrome in Congenital Heart Disease. Thorac Cardiovasc Surg 2022. [DOI: 10.1055/s-0042-1743019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Affiliation(s)
- V. Icheva
- Universtiy Childrens' Hospital Tübingen, Tübingen, Deutschland
| | - J. Ebert
- Faculty of Medicine, Eberhard Karls University, Tübingen, Deutschland
| | - U. Budde
- cMEDILYS Coagulation Lab mbH, Hamburg, Deutschland
| | - G. Wiegand
- Department of Pediatric Cardiology, University of Tuebingen, Tuebingen, Deutschland
| | - S. Schober
- Universtiy Childrens' Hospital Tübingen, Tübingen, Deutschland
| | - J. Engel
- Department of Pediatric Cardiology, University Childrens' Hospital Tübingen, Tuebingen, Deutschland
| | - M. Kumpf
- Department of Pediatric Cardiology, University of Tuebingen, Tuebingen, Deutschland
| | - K. Jaschonek
- Department of Medical Oncology and Pneumology (Internal Medicine VIII), University Hospital Tübingen, Tuebingen, Deutschland
| | - F. Neunhoeffer
- Abteilung für Kinderkardiologie, Pulmologie, Intensivmedizin, Tübingen, Deutschland
| | - J. Michel
- Department of Pediatric Cardiology, University Childrens' Hospital Tübingen, Tuebingen, Deutschland
| | | | - M. Hofbeck
- Hoppe-Seyler-Str. 1, Tübingen, Deutschland
| | - H. Magunia
- Department of Anesthesiology and Intensive Care Medicine, Tübingen, Germany
| |
Collapse
|
14
|
Grigioni S, Savoye-Collet C, Tamion F, Van Elslande H, Gâté M, Traore-Ouattara U, Marais B, Michel J, Déchelotte P, Lvovschi VE, Achamrah N. Low thoracic skeletal muscle index is associated with negative outcomes in 244 patients with covid-19. Clin Nutr ESPEN 2021. [PMCID: PMC8629553 DOI: 10.1016/j.clnesp.2021.09.050] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
15
|
Alvarez-Covarrubias HA, Michel J, Xhepa E, Mayr NP, Pellegrini C, Rheude T, Kasel AM, Joner M, Borrayo-Sanchez G. Correlation between fluoroscopy and tomographic aortic-root measurements in the decision of the transcatheter heart valve size in patients undergoing transcatheter aortic valve implantation. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.1658] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Introduction and hypothesis
Transcatheter aortic valve implantation (TAVI) has become the standard treatment in intermediate and high-risk patients with high degree aortic stenosis (AS).(1–2) These has been also extended to low-risk and younger patients.(3–5) Besides the use of computed-tomography (CT) as diagnostic method to measure the aortic anatomy for transcatheter heart valve (THV) size decision and the radiation exposure (RE) during TAVI, younger patients are more exposed to radiation and contrast media (CM) complications due to a potentially second procedure.(6) Reducing RE and CM using only angiography aortic measurement could reduce the risk of RE and CM related complications without compromising the efficacy of the THV. We hypothesize that angiographic aortic root (AR) measure has good correlation with CT measure without compromising safety and efficacy of the THV.
Methods
Observational analysis: 1250 transfemoral TAVI patients with balloon or self-expandable valves were included. Aortic root CT measurement was done in all patients. AR measurement using Follow the right cup rule (7) was additionally done in 505 patients. Correlation between CT only (Group I n=745) versus CT and AR measurement (Group II n=505) was done. An inter and intraobserver validation analysis was done. Primary endpoint was VARC-2 device success. Secondary safety endpoints were composite of in-hospital and 30-days complications.
Results
Really good intra (0.86, p<0.001) and interobserver (0.81, p<0.001) correlation between CT (mean aortic diameter, distance between non (NC-HP) and left cusp hinge points (LC-HP) distance) and angiographic (LC-HP distance) measurements was observed. CT and AR measurement had a very good correlation between the two groups (CT mean aortic diameter vs CT NC-HP and LC-HP distance, 0.724 p<0.001; CT NC-HP and LC-HP distance vs angiographic NC-HP and LC-HP distance manual calibration 0.808 p<0.001; angiographic NC-HP and LC-HP distance manual calibration vs angiographic NC-HP and LC-HP distance automatic calibration 0.930 p<0.001). No differences in primary endpoint were observed between groups (device success Group I 98% vs Group II 99%, p 0.18). In-hospital complications were similar between two groups except in major bleeding (13% vs 19%, p 0.004), major vascular (10.9% vs 16.6%, p 0.004) and minor vascular (14% vs 21%, p 0.001) between group I and II respectively. Valve safety (86% vs 77%, p<0.001, OR 0.89, 95% CI 0.85–0.95) and clinical efficacy (84% vs 60.8%, p<0.001, OR 0.72, 95% CI 0.67–0.77) at 30 days were more common in group II. No difference in valve dysfunction was observed (Group I 10.3% vs Group II 7.3%, p 0.042, OR 1.41, 95% CI 0.97–2.05).
Conclusions
Compared to CT, AR measurement is a good option selecting THV size. No differences regarding device success and in-hospital and 30 days follow-up complications were observed. AR measurement could replace CT in specific cases.
Funding Acknowledgement
Type of funding sources: None. Angiographic and CT measurementsEndpoints
Collapse
Affiliation(s)
| | - J Michel
- University Hospital Zurich, Cardiology, Zurich, Switzerland
| | - E Xhepa
- Deutsches Herzzentrum Muenchen Technical University of Munich, Munich, Germany
| | - N P Mayr
- Deutsches Herzzentrum Muenchen Technical University of Munich, Munich, Germany
| | - C Pellegrini
- Deutsches Herzzentrum Muenchen Technical University of Munich, Munich, Germany
| | - T Rheude
- Deutsches Herzzentrum Muenchen Technical University of Munich, Munich, Germany
| | - A M Kasel
- University Hospital Zurich, Cardiology, Zurich, Switzerland
| | - M Joner
- Deutsches Herzzentrum Muenchen Technical University of Munich, Munich, Germany
| | | |
Collapse
|
16
|
Michel J, Lemaire N, Joly LM. Une bactériémie à Vibrio cholerae non cholérique. Ann Fr Med Urgence 2021. [DOI: 10.3166/afmu-2021-0347] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
17
|
Lechien JR, Chiesa‐Estomba CM, Radulesco T, Michel J, Vaira LA, Le Bon SD, Horoi M, Falanga C, Barillari MR, Hans S, Tucciarone M, Saussez S. Clinical features of patients who had two COVID-19 episodes: a European multicentre case series. J Intern Med 2021; 290:421-429. [PMID: 33527495 PMCID: PMC8013656 DOI: 10.1111/joim.13259] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/14/2021] [Accepted: 01/25/2021] [Indexed: 12/21/2022]
Abstract
OBJECTIVE To investigate the clinical features of patients who had two demonstrated coronavirus disease 2019 (COVID-19) episodes. METHODS Data of patients with both COVID-19 episodes were recruited from 22 March to 27 December 2020. The following outcomes were studied: epidemiological, comorbidities, prevalence and severity of general and otolaryngological symptom, olfactory, aroma, and gustatory dysfunctions. A comparison between first and second episodes was performed. RESULTS Forty-five patients reported having two confirmed COVID-19 episodes. The majority of patients had mild infections in both episodes. The second clinical episode was significantly similar to the first. The symptom duration of the second episode was shorter than the first. The occurrence of loss of smell was unpredictable from the first to the second episode. CONCLUSION The recurrence of COVID-19 symptoms is associated with a similar clinical picture than the first episode in patients with initial mild-to-moderate COVID episode. The pathophysiological mechanisms underlying the development of second episode remain uncertain and may involve either true reinfection or virus reactivation from sanctuaries.
Collapse
Affiliation(s)
- J. R. Lechien
- From theCOVID‐19 Task Force of the Young‐Otolaryngologists of the International Federations of Oto‐rhino‐laryngological Societies (YO‐IFOS)ParisFrance
- Department of Human Anatomy and Experimental OncologyFaculty of MedicineUMONS Research Institute for Health Sciences and TechnologyUniversity of Mons (UMons)MonsBelgium
- Department of Otolaryngology‐Head & Neck SurgeryFoch HospitalSchool of MedicineUFR Simone VeilUniversité Versailles Saint‐Quentin‐en‐Yvelines (Paris Saclay University)ParisFrance
- Department of Otorhinolaryngology and Head and Neck SurgeryCHU de BruxellesCHU Saint‐PierreSchool of MedicineUniversité Libre de BruxellesBrusselsBelgium
| | - C. M. Chiesa‐Estomba
- From theCOVID‐19 Task Force of the Young‐Otolaryngologists of the International Federations of Oto‐rhino‐laryngological Societies (YO‐IFOS)ParisFrance
- Department of Otorhinolaryngology— Head & Neck SurgeryHospital Universitario DonostiaSan SebastianSpain
| | - T. Radulesco
- From theCOVID‐19 Task Force of the Young‐Otolaryngologists of the International Federations of Oto‐rhino‐laryngological Societies (YO‐IFOS)ParisFrance
- Department of Otorhinolaryngology‐Head & Neck SurgeryAP‐HM, Hopital La ConceptionMarseilleFrance
| | - J. Michel
- From theCOVID‐19 Task Force of the Young‐Otolaryngologists of the International Federations of Oto‐rhino‐laryngological Societies (YO‐IFOS)ParisFrance
- Department of Otorhinolaryngology‐Head & Neck SurgeryAP‐HM, Hopital La ConceptionMarseilleFrance
| | - L. A. Vaira
- From theCOVID‐19 Task Force of the Young‐Otolaryngologists of the International Federations of Oto‐rhino‐laryngological Societies (YO‐IFOS)ParisFrance
- Maxillofacial Surgery UnitUniversity Hospital of SassariSassariItaly
| | - S. D. Le Bon
- From theCOVID‐19 Task Force of the Young‐Otolaryngologists of the International Federations of Oto‐rhino‐laryngological Societies (YO‐IFOS)ParisFrance
- Department of Otorhinolaryngology and Head and Neck SurgeryCHU de BruxellesCHU Saint‐PierreSchool of MedicineUniversité Libre de BruxellesBrusselsBelgium
| | - M. Horoi
- Department of Otorhinolaryngology and Head and Neck SurgeryCHU de BruxellesCHU Saint‐PierreSchool of MedicineUniversité Libre de BruxellesBrusselsBelgium
| | - C. Falanga
- From theCOVID‐19 Task Force of the Young‐Otolaryngologists of the International Federations of Oto‐rhino‐laryngological Societies (YO‐IFOS)ParisFrance
- Division of Phoniatrics and AudiologyDepartment of Mental and Physical Health and Preventive MedicineUniversity of L. VanvitelliNaplesItaly
| | - M. R. Barillari
- From theCOVID‐19 Task Force of the Young‐Otolaryngologists of the International Federations of Oto‐rhino‐laryngological Societies (YO‐IFOS)ParisFrance
- Division of Phoniatrics and AudiologyDepartment of Mental and Physical Health and Preventive MedicineUniversity of L. VanvitelliNaplesItaly
| | - S. Hans
- From theCOVID‐19 Task Force of the Young‐Otolaryngologists of the International Federations of Oto‐rhino‐laryngological Societies (YO‐IFOS)ParisFrance
- Department of Otolaryngology‐Head & Neck SurgeryFoch HospitalSchool of MedicineUFR Simone VeilUniversité Versailles Saint‐Quentin‐en‐Yvelines (Paris Saclay University)ParisFrance
| | - M. Tucciarone
- From theCOVID‐19 Task Force of the Young‐Otolaryngologists of the International Federations of Oto‐rhino‐laryngological Societies (YO‐IFOS)ParisFrance
- ENT Department Hospital Universitario de JerezJerez de la FronteraSpain
| | - S. Saussez
- From theCOVID‐19 Task Force of the Young‐Otolaryngologists of the International Federations of Oto‐rhino‐laryngological Societies (YO‐IFOS)ParisFrance
- Department of Human Anatomy and Experimental OncologyFaculty of MedicineUMONS Research Institute for Health Sciences and TechnologyUniversity of Mons (UMons)MonsBelgium
- Department of Otolaryngology‐Head & Neck SurgeryFoch HospitalSchool of MedicineUFR Simone VeilUniversité Versailles Saint‐Quentin‐en‐Yvelines (Paris Saclay University)ParisFrance
- Department of Otorhinolaryngology and Head and Neck SurgeryCHU de BruxellesCHU Saint‐PierreSchool of MedicineUniversité Libre de BruxellesBrusselsBelgium
| |
Collapse
|
18
|
Djemai K, Gouriet F, Michel J, Radulesco T, Drancourt M, Grine G. Methanobrevibacter smithii tonsillar phlegmon: a case report. New Microbes New Infect 2021; 42:100891. [PMID: 34141438 PMCID: PMC8184653 DOI: 10.1016/j.nmni.2021.100891] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2021] [Revised: 04/21/2021] [Accepted: 04/22/2021] [Indexed: 12/22/2022] Open
Abstract
Untreated tonsillar phlegmon is a life-threatening condition commonly caused by Streptococcus pyogenes and Fusobacterium necrophorum, among other pathogens. Here, using specific laboratory tools, we detected Methanobrevibacter smithii in addition to S. pyogenes. This unprecedented observation questions the role of methanogens in phlegmon and the optimal treatment of this mixed infection.
Collapse
Affiliation(s)
- K Djemai
- Aix-Marseille Univ, IRD, MEPHI, Marseille, France.,IHU Méditerranée Infection, Marseille, France
| | - F Gouriet
- Aix-Marseille Univ, IRD, MEPHI, Marseille, France.,IHU Méditerranée Infection, Marseille, France
| | - J Michel
- CHU Hôpital de la Conception, Service ORL et Chirurgie cervico-faciale, Marseille, France
| | - T Radulesco
- CHU Hôpital de la Conception, Service ORL et Chirurgie cervico-faciale, Marseille, France
| | - M Drancourt
- Aix-Marseille Univ, IRD, MEPHI, Marseille, France.,IHU Méditerranée Infection, Marseille, France
| | - G Grine
- IHU Méditerranée Infection, Marseille, France.,Aix-Marseille Université, UFR Odontologie, Marseille, France
| |
Collapse
|
19
|
Dahan LS, Giorgi R, Vergez S, Le Taillandier de Gabory L, Costes-Martineau V, Herman P, Poissonnet G, Mauvais O, Malard O, Garrel R, Uro-Coste E, Barry B, Bach C, Chevalier D, Mouawad F, Merol JC, Bastit V, Thariat J, Gilain L, Dufour X, Righini CA, Moya-Plana A, Even C, Radulesco T, Michel J, Baujat B, Fakhry N, Albert S, Andry G, Babin E, Bach C, Badet JM, Badoual C, Baglin A, Banal A, Barry B, Baudin E, Baujat B, Bensadoun R, Bertolus C, Bessède JP, Blanchard D, Borel C, Bozorg-Grayeli A, Breheret R, Breton P, Brugel L, Calais G, Casiraghi O, Cassagnau E, Castillo L, Ceruse P, Chabolle F, Chevalier D, Chobaut J, Choussy O, Cosmidis A, Coste A, Costes V, Crampette L, Darrouzet V, Demez P, Dessi P, Devauchelle B, Dolivet G, Dubrulle F, Duflo S, Dufour X, Faivre S, Fakhry N, Ferron C, Floret F, de Gabory L, Garrel R, Geoffrois L, Gilain L, Giovanni A, Girod A, Guerrier B, Hans S, Herman P, Hofman P, Housset M, Jankowski R, Jegoux F, Juliéron M, Kaminsky MC, Kolb F, St Guily JL, Laccoureye L, Lallemant B, Lang P, Lartigau E, Lavieille JP, Lefevre M, Leroy X, Malard O, Massip F, Mauvais O, Merol JC, Michel J, Mom T, Morinière S, de Monès E, Moulin G, Noel G, Poissonnet G, Prades JM, Radulesco T, de Raucourt D, Reyt E, Righini C, Robin YM, Rolland F, Ruhin B, Sarroul N, Schultz P, Serrano E, Sterkers O, Strunski V, Sudaka A, Tassart M, Testelin S, Thariat J, Timochenko A, Toussaint B, Coste EU, Valette G, Van den Abbeele T, Varoquaux A, Veillon F, Vergez S, Wassef M. Mucoepidermoid carcinoma of salivary glands: A French Network of Rare Head and Neck Tumors (REFCOR) prospective study of 292 cases. Eur J Surg Oncol 2021; 47:1376-1383. [DOI: 10.1016/j.ejso.2020.11.123] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2020] [Revised: 10/31/2020] [Accepted: 11/13/2020] [Indexed: 12/18/2022] Open
|
20
|
Radulesco T, Penicaud M, Michel J. Upper blepharoplasty: The standard procedure (with video). Eur Ann Otorhinolaryngol Head Neck Dis 2021; 138 Suppl 4:141-142. [PMID: 34083170 DOI: 10.1016/j.anorl.2020.10.014] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2020] [Revised: 09/25/2020] [Accepted: 10/13/2020] [Indexed: 10/21/2022]
Affiliation(s)
- T Radulesco
- Department of Oto-Rhino-Laryngology and Head and Neck Surgery, APHM, La Conception University Hospital, Marseille, France; CNRS, IUSTI, Aix Marseille University, Marseille, France.
| | - M Penicaud
- Department of Oto-Rhino-Laryngology and Head and Neck Surgery, APHM, La Conception University Hospital, Marseille, France
| | - J Michel
- Department of Oto-Rhino-Laryngology and Head and Neck Surgery, APHM, La Conception University Hospital, Marseille, France; CNRS, IUSTI, Aix Marseille University, Marseille, France
| |
Collapse
|
21
|
Abou Khalil Y, Azar Y, El Bitar S, Lebel M, Deschildre C, Ghaleb Y, Dupont S, Guillas I, Le Goff W, Le Goff C, Boileau C, Varret M, Abifadel M, Michel J, El Khoury P. PCSK9 in the development of human atherosclerosis. Archives of Cardiovascular Diseases Supplements 2021. [DOI: 10.1016/j.acvdsp.2021.04.083] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
22
|
Laccourreye O, Fakhry N, Franco-Vidal V, Jankowski R, Karkas A, Leboulanger N, Makeief M, Malard O, Michel J, Righini C, Rumeau C, Vincent C, Lisan Q. Statistics in scientific articles published in the European Annals of Otorhinolaryngology Head & Neck Diseases. Eur Ann Otorhinolaryngol Head Neck Dis 2021; 138:89-92. [DOI: 10.1016/j.anorl.2020.06.015] [Citation(s) in RCA: 32] [Impact Index Per Article: 10.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
23
|
Fodil S, Raffoux E, Dumas PY, Desbrosses Y, Larosa F, Chantepie S, Larcher MV, Mear JB, Peterlin P, Hunault-Berger M, Hospital MA, Morel V, Lucas N, Vidal V, Salanoubat C, Michel J, Mediavilla C, Ojeda-Uribe M, Alexis M, Frayfer J, Carré M, Maillard N, Redjoul R, Banos A, Detrait M, Cluzeau T, Wickenhauser S, Chaoui D, Elassy M, Pigneux A, Dombret H, Récher C, Bertoli S. Data from French named patient program of quizartinib in relapsed/refractory acute myeloid leukemia. Leuk Lymphoma 2021; 62:1756-1760. [PMID: 33596765 DOI: 10.1080/10428194.2021.1881505] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Affiliation(s)
- S Fodil
- Service d'Hématologie adulte, Hôpital Saint-Louis, Assistance Publique Hôpitaux de Paris, Paris, France
| | - E Raffoux
- Service d'Hématologie adulte, Hôpital Saint-Louis, Assistance Publique Hôpitaux de Paris, Paris, France
| | - P Y Dumas
- Service d'Hématologie, CHU Bordeaux, F-33000, Bordeaux, France
| | - Y Desbrosses
- Service d'Hématologie, CHRU Jean Minjoz, Besançon, France
| | - F Larosa
- Service d'Hématologie, CHU de Dijon, Dijon, France
| | - S Chantepie
- Service d'Hématologie, Institut d'Hématologie de Basse-Normandie CHU de Caen, Caen, France
| | - M V Larcher
- Service d'Hématologie, Hospices civils de Lyon, CHU de Lyon, Lyon, France
| | - J B Mear
- Service d'Hématologie, CHU de Rennes - Hôpital Pontchaillou, Rennes, France
| | - P Peterlin
- Service d'Hématologie, CHU de Nantes, Nantes, France
| | - M Hunault-Berger
- Service des Maladies du Sang, Centre Hospitalier Universitaire, FHU GOAL, CRCINA, INSERM, Angers, France
| | - M A Hospital
- Service d'Hématologie, Institut Paoli-Calmettes, Marseille, France
| | - V Morel
- Service d'Hématologie, Hôpital Pitié-Salpêtrière AP-HP, Paris, France
| | - N Lucas
- Service d'Hématologie, Institut Gustave Roussy, Villejuif, France
| | - V Vidal
- Service d'Hématologie, Hôpital Avicenne AP-HP, Bobigny, France
| | - C Salanoubat
- Service d'Hématologie, C.H. Sud Francilien, Corbeil-Essonnes, France
| | - J Michel
- Service d'Hématologie, C.H.R. - Hôpital Félix Maréchal, Metz-Thionville, France
| | - C Mediavilla
- Service d'Hématologie, Hôpital Saint-Antoine AP-HP, Paris, France
| | - M Ojeda-Uribe
- Service d'Hématologie, Groupe Hospitalier Régional Mulhouse Sud-Alsace, Mulhouse, France
| | - M Alexis
- Service d'Hématologie, CHR Orléans, Orléans, France
| | - J Frayfer
- Service d'Hématologie, Grand Hôpital de l'Est Francilien - Site de Meaux, Meaux, France
| | - M Carré
- Service d'Hématologie, CHU Grenoble Alpes, La Tronche, France
| | - N Maillard
- Service d'Hématologie, CHU de Poitiers, Poitiers, France
| | - R Redjoul
- Service d'Hématologie, CHU Henri Mondor, AP-HP et UPEC, Créteil, France
| | - A Banos
- Service d'Hématologie, Centre hospitalier de la côte basque, Bayonne, France
| | - M Detrait
- Service d'Hématologie, CHRU de Nancy, Nancy, France
| | - T Cluzeau
- Département d'Hématologie, Université Cote d'Azur, CHU de Nice, Nice, France
| | | | - D Chaoui
- Service d'Hématologie, CH d'Argenteuil, Argenteuil, France
| | - M Elassy
- Service d'Hématologie, CH d'Auxerre, Auxerre, France
| | - A Pigneux
- Service d'Hématologie, CHU Bordeaux, F-33000, Bordeaux, France
| | - H Dombret
- Service d'Hématologie adulte, Hôpital Saint-Louis, Assistance Publique Hôpitaux de Paris, Paris, France
| | - C Récher
- Service d'Hématologie, CHU de Toulouse, Centre de Recherches en Cancérologie de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole, Université de Toulouse 3 Paul Sabatier, Toulouse, France
| | - S Bertoli
- Service d'Hématologie, CHU de Toulouse, Centre de Recherches en Cancérologie de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole, Université de Toulouse 3 Paul Sabatier, Toulouse, France
| | | |
Collapse
|
24
|
Trouvé G, Ngo C, Almouallem W, Joyeux C, Dorge S, Michel J, Nouen DL. Development of a Liquid/Liquid Extraction Method and GC/MS Analysis Dedicated to the Quantitative Analysis of PAHs and O-PACs in Groundwater from Contaminated Sites and Soils. Polycycl Aromat Compd 2021. [DOI: 10.1080/10406638.2021.1880449] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Affiliation(s)
- G. Trouvé
- Laboratoire Gestion des Risques et Environnement, Université de Haute Alsace, Mulhouse, France
| | - C. Ngo
- Laboratoire Gestion des Risques et Environnement, Université de Haute Alsace, Mulhouse, France
- Laboratoire d’Innovation Moléculaire et Applications, Université de Haute Alsace, Mulhouse, France
| | - W. Almouallem
- Laboratoire Gestion des Risques et Environnement, Université de Haute Alsace, Mulhouse, France
- Laboratoire d’Innovation Moléculaire et Applications, Université de Haute Alsace, Mulhouse, France
- Institut National de l’Environnement Industriel et des Risques, Verneuil en Halatte, France
- Agence De l’Environnement et de la Maîtrise de l’Energie, Angers, France
| | - C. Joyeux
- Laboratoire d’Innovation Moléculaire et Applications, Université de Haute Alsace, Mulhouse, France
| | - S. Dorge
- Laboratoire Gestion des Risques et Environnement, Université de Haute Alsace, Mulhouse, France
| | - J. Michel
- Institut National de l’Environnement Industriel et des Risques, Verneuil en Halatte, France
| | - D. Le Nouen
- Laboratoire d’Innovation Moléculaire et Applications, Université de Haute Alsace, Mulhouse, France
| |
Collapse
|
25
|
Adamczewski-Musch J, Arnold O, Behnke C, Belounnas A, Belyaev A, Berger-Chen JC, Blanco A, Blume C, Böhmer M, Bordalo P, Chernenko S, Chlad L, Ciepal I, Deveaux C, Dreyer J, Epple E, Fabbietti L, Fateev O, Filip P, Fonte P, Franco C, Friese J, Fröhlich I, Galatyuk T, Garzón JA, Gernhäuser R, Golosov O, Golubeva M, Greifenhagen R, Guber F, Gumberidze M, Harabasz S, Heinz T, Hennino T, Hlavac S, Höhne C, Holzmann R, Ierusalimov A, Ivashkin A, Kämpfer B, Karavicheva T, Kardan B, Koenig I, Koenig W, Kohls M, Kolb BW, Korcyl G, Kornakov G, Kornas F, Kotte R, Kugler A, Kunz T, Kurepin A, Kurilkin A, Kurilkin P, Ladygin V, Lalik R, Lapidus K, Lebedev A, Lopes L, Lorenz M, Mahmoud T, Maier L, Malige A, Mamaev M, Mangiarotti A, Markert J, Matulewicz T, Maurus S, Metag V, Michel J, Mihaylov DM, Morozov S, Müntz C, Münzer R, Naumann L, Nowakowski K, Parpottas Y, Pechenov V, Pechenova O, Petukhov O, Piasecki K, Pietraszko J, Przygoda W, Pysz K, Ramos S, Ramstein B, Rathod N, Reshetin A, Rodriguez-Ramos P, Rosier P, Rost A, Rustamov A, Sadovsky A, Salabura P, Scheib T, Schuldes H, Schwab E, Scozzi F, Seck F, Sellheim P, Selyuzhenkov I, Siebenson J, Silva L, Singh U, Smyrski J, Sobolev YG, Spataro S, Spies S, Ströbele H, Stroth J, Sturm C, Svoboda O, Szala M, Tlusty P, Traxler M, Tsertos H, Usenko E, Wagner V, Wendisch C, Wiebusch MG, Wirth J, Wójcik D, Zanevsky Y, Zumbruch P. Directed, Elliptic, and Higher Order Flow Harmonics of Protons, Deuterons, and Tritons in Au+Au Collisions at sqrt[s_{NN}]=2.4 GeV. Phys Rev Lett 2020; 125:262301. [PMID: 33449792 DOI: 10.1103/physrevlett.125.262301] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/26/2020] [Revised: 10/07/2020] [Accepted: 11/29/2020] [Indexed: 06/12/2023]
Abstract
Flow coefficients v_{n} of the orders n=1-6 are measured with the High-Acceptance DiElectron Spectrometer (HADES) at GSI for protons, deuterons, and tritons as a function of centrality, transverse momentum, and rapidity in Au+Au collisions at sqrt[s_{NN}]=2.4 GeV. Combining the information from the flow coefficients of all orders allows us to construct for the first time, at collision energies of a few GeV, a multidifferential picture of the angular emission pattern of these particles. It reflects the complicated interplay between the effect of the central fireball pressure on the emission of particles and their subsequent interaction with spectator matter. The high precision information on higher order flow coefficients is a major step forward in constraining the equation of state of dense baryonic matter.
Collapse
Affiliation(s)
- J Adamczewski-Musch
- GSI Helmholtzzentrum für Schwerionenforschung GmbH, 64291 Darmstadt, Germany
| | - O Arnold
- Excellence Cluster "Origin and Structure of the Universe," 85748 Garching, Germany
- Physik Department E62, Technische Universität München, 85748 Garching, Germany
| | - C Behnke
- Institut für Kernphysik, Goethe-Universität, 60438 Frankfurt, Germany
| | - A Belounnas
- Laboratoire de Physique des 2 infinis Irène Joliot-Curie, Université Paris-Saclay, CNRS-IN2P3, F-91405 Orsay, France
| | - A Belyaev
- Joint Institute of Nuclear Research, 141980 Dubna, Russia
| | - J C Berger-Chen
- Excellence Cluster "Origin and Structure of the Universe," 85748 Garching, Germany
- Physik Department E62, Technische Universität München, 85748 Garching, Germany
| | - A Blanco
- LIP-Laboratório de Instrumentação e Física Experimental de Partículas, 3004-516 Coimbra, Portugal
| | - C Blume
- Institut für Kernphysik, Goethe-Universität, 60438 Frankfurt, Germany
| | - M Böhmer
- Physik Department E62, Technische Universität München, 85748 Garching, Germany
| | - P Bordalo
- LIP-Laboratório de Instrumentação e Física Experimental de Partículas, 3004-516 Coimbra, Portugal
| | - S Chernenko
- Joint Institute of Nuclear Research, 141980 Dubna, Russia
| | - L Chlad
- Nuclear Physics Institute, The Czech Academy of Sciences, 25068 Rez, Czech Republic
| | - I Ciepal
- Institute of Nuclear Physics, Polish Academy of Sciences, 31342 Kraków, Poland
| | - C Deveaux
- II.Physikalisches Institut, Justus Liebig Universität Giessen, 35392 Giessen, Germany
| | - J Dreyer
- Institut für Strahlenphysik, Helmholtz-Zentrum Dresden-Rossendorf, 01314 Dresden, Germany
| | - E Epple
- Excellence Cluster "Origin and Structure of the Universe," 85748 Garching, Germany
- Physik Department E62, Technische Universität München, 85748 Garching, Germany
| | - L Fabbietti
- Excellence Cluster "Origin and Structure of the Universe," 85748 Garching, Germany
- Physik Department E62, Technische Universität München, 85748 Garching, Germany
| | - O Fateev
- Joint Institute of Nuclear Research, 141980 Dubna, Russia
| | - P Filip
- Institute of Physics, Slovak Academy of Sciences, 84228 Bratislava, Slovakia
| | - P Fonte
- LIP-Laboratório de Instrumentação e Física Experimental de Partículas, 3004-516 Coimbra, Portugal
| | - C Franco
- LIP-Laboratório de Instrumentação e Física Experimental de Partículas, 3004-516 Coimbra, Portugal
| | - J Friese
- Physik Department E62, Technische Universität München, 85748 Garching, Germany
| | - I Fröhlich
- Institut für Kernphysik, Goethe-Universität, 60438 Frankfurt, Germany
| | - T Galatyuk
- GSI Helmholtzzentrum für Schwerionenforschung GmbH, 64291 Darmstadt, Germany
- Technische Universität Darmstadt, 64289 Darmstadt, Germany
| | - J A Garzón
- LabCAF. F. Física, Universidad de Santiago de Compostela, 15706 Santiago de Compostela, Spain
| | - R Gernhäuser
- Physik Department E62, Technische Universität München, 85748 Garching, Germany
| | - O Golosov
- National Research Nuclear University MEPhI (Moscow Engineering Physics Institute), 115409 Moscow, Russia
| | - M Golubeva
- Institute for Nuclear Research, Russian Academy of Science, 117312 Moscow, Russia
| | - R Greifenhagen
- Institut für Strahlenphysik, Helmholtz-Zentrum Dresden-Rossendorf, 01314 Dresden, Germany
| | - F Guber
- Institute for Nuclear Research, Russian Academy of Science, 117312 Moscow, Russia
| | - M Gumberidze
- GSI Helmholtzzentrum für Schwerionenforschung GmbH, 64291 Darmstadt, Germany
- Technische Universität Darmstadt, 64289 Darmstadt, Germany
| | - S Harabasz
- Smoluchowski Institute of Physics, Jagiellonian University of Cracow, 30-059 Kraków, Poland
- Technische Universität Darmstadt, 64289 Darmstadt, Germany
| | - T Heinz
- GSI Helmholtzzentrum für Schwerionenforschung GmbH, 64291 Darmstadt, Germany
| | - T Hennino
- Laboratoire de Physique des 2 infinis Irène Joliot-Curie, Université Paris-Saclay, CNRS-IN2P3, F-91405 Orsay, France
| | - S Hlavac
- Institute of Physics, Slovak Academy of Sciences, 84228 Bratislava, Slovakia
| | - C Höhne
- GSI Helmholtzzentrum für Schwerionenforschung GmbH, 64291 Darmstadt, Germany
- II.Physikalisches Institut, Justus Liebig Universität Giessen, 35392 Giessen, Germany
| | - R Holzmann
- GSI Helmholtzzentrum für Schwerionenforschung GmbH, 64291 Darmstadt, Germany
| | - A Ierusalimov
- Joint Institute of Nuclear Research, 141980 Dubna, Russia
| | - A Ivashkin
- Institute for Nuclear Research, Russian Academy of Science, 117312 Moscow, Russia
| | - B Kämpfer
- Institut für Strahlenphysik, Helmholtz-Zentrum Dresden-Rossendorf, 01314 Dresden, Germany
| | - T Karavicheva
- Institute for Nuclear Research, Russian Academy of Science, 117312 Moscow, Russia
| | - B Kardan
- Institut für Kernphysik, Goethe-Universität, 60438 Frankfurt, Germany
| | - I Koenig
- GSI Helmholtzzentrum für Schwerionenforschung GmbH, 64291 Darmstadt, Germany
| | - W Koenig
- GSI Helmholtzzentrum für Schwerionenforschung GmbH, 64291 Darmstadt, Germany
| | - M Kohls
- Institut für Kernphysik, Goethe-Universität, 60438 Frankfurt, Germany
| | - B W Kolb
- GSI Helmholtzzentrum für Schwerionenforschung GmbH, 64291 Darmstadt, Germany
| | - G Korcyl
- Smoluchowski Institute of Physics, Jagiellonian University of Cracow, 30-059 Kraków, Poland
| | - G Kornakov
- Technische Universität Darmstadt, 64289 Darmstadt, Germany
| | - F Kornas
- Technische Universität Darmstadt, 64289 Darmstadt, Germany
| | - R Kotte
- Institut für Strahlenphysik, Helmholtz-Zentrum Dresden-Rossendorf, 01314 Dresden, Germany
| | - A Kugler
- Nuclear Physics Institute, The Czech Academy of Sciences, 25068 Rez, Czech Republic
| | - T Kunz
- Physik Department E62, Technische Universität München, 85748 Garching, Germany
| | - A Kurepin
- Institute for Nuclear Research, Russian Academy of Science, 117312 Moscow, Russia
| | - A Kurilkin
- Joint Institute of Nuclear Research, 141980 Dubna, Russia
| | - P Kurilkin
- Joint Institute of Nuclear Research, 141980 Dubna, Russia
| | - V Ladygin
- Joint Institute of Nuclear Research, 141980 Dubna, Russia
| | - R Lalik
- Smoluchowski Institute of Physics, Jagiellonian University of Cracow, 30-059 Kraków, Poland
| | - K Lapidus
- Excellence Cluster "Origin and Structure of the Universe," 85748 Garching, Germany
- Physik Department E62, Technische Universität München, 85748 Garching, Germany
| | - A Lebedev
- Institute of Theoretical and Experimental Physics, 117218 Moscow, Russia
| | - L Lopes
- LIP-Laboratório de Instrumentação e Física Experimental de Partículas, 3004-516 Coimbra, Portugal
| | - M Lorenz
- Institut für Kernphysik, Goethe-Universität, 60438 Frankfurt, Germany
| | - T Mahmoud
- II.Physikalisches Institut, Justus Liebig Universität Giessen, 35392 Giessen, Germany
| | - L Maier
- Physik Department E62, Technische Universität München, 85748 Garching, Germany
| | - A Malige
- Smoluchowski Institute of Physics, Jagiellonian University of Cracow, 30-059 Kraków, Poland
| | - M Mamaev
- National Research Nuclear University MEPhI (Moscow Engineering Physics Institute), 115409 Moscow, Russia
| | - A Mangiarotti
- LIP-Laboratório de Instrumentação e Física Experimental de Partículas, 3004-516 Coimbra, Portugal
| | - J Markert
- GSI Helmholtzzentrum für Schwerionenforschung GmbH, 64291 Darmstadt, Germany
| | - T Matulewicz
- Uniwersytet Warszawski, Wydział Fizyki, Instytut Fizyki Doświadczalnej, 02-093 Warszawa, Poland
| | - S Maurus
- Physik Department E62, Technische Universität München, 85748 Garching, Germany
| | - V Metag
- II.Physikalisches Institut, Justus Liebig Universität Giessen, 35392 Giessen, Germany
| | - J Michel
- Institut für Kernphysik, Goethe-Universität, 60438 Frankfurt, Germany
| | - D M Mihaylov
- Excellence Cluster "Origin and Structure of the Universe," 85748 Garching, Germany
- Physik Department E62, Technische Universität München, 85748 Garching, Germany
| | - S Morozov
- Institute for Nuclear Research, Russian Academy of Science, 117312 Moscow, Russia
- National Research Nuclear University MEPhI (Moscow Engineering Physics Institute), 115409 Moscow, Russia
| | - C Müntz
- Institut für Kernphysik, Goethe-Universität, 60438 Frankfurt, Germany
| | - R Münzer
- Excellence Cluster "Origin and Structure of the Universe," 85748 Garching, Germany
- Physik Department E62, Technische Universität München, 85748 Garching, Germany
| | - L Naumann
- Institut für Strahlenphysik, Helmholtz-Zentrum Dresden-Rossendorf, 01314 Dresden, Germany
| | - K Nowakowski
- Smoluchowski Institute of Physics, Jagiellonian University of Cracow, 30-059 Kraków, Poland
| | - Y Parpottas
- Department of Physics, University of Cyprus, 1678 Nicosia, Cyprus
| | - V Pechenov
- GSI Helmholtzzentrum für Schwerionenforschung GmbH, 64291 Darmstadt, Germany
| | - O Pechenova
- GSI Helmholtzzentrum für Schwerionenforschung GmbH, 64291 Darmstadt, Germany
| | - O Petukhov
- Institute for Nuclear Research, Russian Academy of Science, 117312 Moscow, Russia
| | - K Piasecki
- Uniwersytet Warszawski, Wydział Fizyki, Instytut Fizyki Doświadczalnej, 02-093 Warszawa, Poland
| | - J Pietraszko
- GSI Helmholtzzentrum für Schwerionenforschung GmbH, 64291 Darmstadt, Germany
| | - W Przygoda
- Smoluchowski Institute of Physics, Jagiellonian University of Cracow, 30-059 Kraków, Poland
| | - K Pysz
- Institute of Nuclear Physics, Polish Academy of Sciences, 31342 Kraków, Poland
| | - S Ramos
- LIP-Laboratório de Instrumentação e Física Experimental de Partículas, 3004-516 Coimbra, Portugal
| | - B Ramstein
- Laboratoire de Physique des 2 infinis Irène Joliot-Curie, Université Paris-Saclay, CNRS-IN2P3, F-91405 Orsay, France
| | - N Rathod
- Smoluchowski Institute of Physics, Jagiellonian University of Cracow, 30-059 Kraków, Poland
| | - A Reshetin
- Institute for Nuclear Research, Russian Academy of Science, 117312 Moscow, Russia
| | - P Rodriguez-Ramos
- Nuclear Physics Institute, The Czech Academy of Sciences, 25068 Rez, Czech Republic
| | - P Rosier
- Laboratoire de Physique des 2 infinis Irène Joliot-Curie, Université Paris-Saclay, CNRS-IN2P3, F-91405 Orsay, France
| | - A Rost
- Technische Universität Darmstadt, 64289 Darmstadt, Germany
| | - A Rustamov
- GSI Helmholtzzentrum für Schwerionenforschung GmbH, 64291 Darmstadt, Germany
| | - A Sadovsky
- Institute for Nuclear Research, Russian Academy of Science, 117312 Moscow, Russia
| | - P Salabura
- Smoluchowski Institute of Physics, Jagiellonian University of Cracow, 30-059 Kraków, Poland
| | - T Scheib
- Institut für Kernphysik, Goethe-Universität, 60438 Frankfurt, Germany
| | - H Schuldes
- Institut für Kernphysik, Goethe-Universität, 60438 Frankfurt, Germany
| | - E Schwab
- GSI Helmholtzzentrum für Schwerionenforschung GmbH, 64291 Darmstadt, Germany
| | - F Scozzi
- Technische Universität Darmstadt, 64289 Darmstadt, Germany
- Laboratoire de Physique des 2 infinis Irène Joliot-Curie, Université Paris-Saclay, CNRS-IN2P3, F-91405 Orsay, France
| | - F Seck
- Technische Universität Darmstadt, 64289 Darmstadt, Germany
| | - P Sellheim
- Institut für Kernphysik, Goethe-Universität, 60438 Frankfurt, Germany
| | - I Selyuzhenkov
- GSI Helmholtzzentrum für Schwerionenforschung GmbH, 64291 Darmstadt, Germany
- National Research Nuclear University MEPhI (Moscow Engineering Physics Institute), 115409 Moscow, Russia
| | - J Siebenson
- Physik Department E62, Technische Universität München, 85748 Garching, Germany
| | - L Silva
- LIP-Laboratório de Instrumentação e Física Experimental de Partículas, 3004-516 Coimbra, Portugal
| | - U Singh
- Smoluchowski Institute of Physics, Jagiellonian University of Cracow, 30-059 Kraków, Poland
| | - J Smyrski
- Smoluchowski Institute of Physics, Jagiellonian University of Cracow, 30-059 Kraków, Poland
| | - Yu G Sobolev
- Nuclear Physics Institute, The Czech Academy of Sciences, 25068 Rez, Czech Republic
| | - S Spataro
- Dipartimento di Fisica and INFN, Università di Torino, 10125 Torino, Italy
| | - S Spies
- Institut für Kernphysik, Goethe-Universität, 60438 Frankfurt, Germany
| | - H Ströbele
- Institut für Kernphysik, Goethe-Universität, 60438 Frankfurt, Germany
| | - J Stroth
- GSI Helmholtzzentrum für Schwerionenforschung GmbH, 64291 Darmstadt, Germany
- Institut für Kernphysik, Goethe-Universität, 60438 Frankfurt, Germany
| | - C Sturm
- GSI Helmholtzzentrum für Schwerionenforschung GmbH, 64291 Darmstadt, Germany
| | - O Svoboda
- Nuclear Physics Institute, The Czech Academy of Sciences, 25068 Rez, Czech Republic
| | - M Szala
- Institut für Kernphysik, Goethe-Universität, 60438 Frankfurt, Germany
| | - P Tlusty
- Nuclear Physics Institute, The Czech Academy of Sciences, 25068 Rez, Czech Republic
| | - M Traxler
- GSI Helmholtzzentrum für Schwerionenforschung GmbH, 64291 Darmstadt, Germany
| | - H Tsertos
- Department of Physics, University of Cyprus, 1678 Nicosia, Cyprus
| | - E Usenko
- Institute for Nuclear Research, Russian Academy of Science, 117312 Moscow, Russia
| | - V Wagner
- Nuclear Physics Institute, The Czech Academy of Sciences, 25068 Rez, Czech Republic
| | - C Wendisch
- GSI Helmholtzzentrum für Schwerionenforschung GmbH, 64291 Darmstadt, Germany
| | - M G Wiebusch
- GSI Helmholtzzentrum für Schwerionenforschung GmbH, 64291 Darmstadt, Germany
| | - J Wirth
- Excellence Cluster "Origin and Structure of the Universe," 85748 Garching, Germany
- Physik Department E62, Technische Universität München, 85748 Garching, Germany
| | - D Wójcik
- Uniwersytet Warszawski, Wydział Fizyki, Instytut Fizyki Doświadczalnej, 02-093 Warszawa, Poland
| | - Y Zanevsky
- Joint Institute of Nuclear Research, 141980 Dubna, Russia
| | - P Zumbruch
- GSI Helmholtzzentrum für Schwerionenforschung GmbH, 64291 Darmstadt, Germany
| |
Collapse
|
26
|
Salabura P, Adamczewski-Musch J, Arnoldi-Meadows B, Belounnas A, Belyaev A, Blanco A, Blume C, Böhmer M, Borisenko S, Chlad L, Chudoba P, Ciepał I, Dittert D, Dreyer J, Esmail W, Dürr M, Fabbietti L, Fateev S, Fonte P, Friese J, Fröhlich I, Förtsch J, Galatyuk T, Gernhäuser R, Golosov O, Golubeva M, Greifenhagen R, Guber F, Gumberidze M, Harabasz S, Hensch R, Höhne C, Holzmann R, Huck H, Ierusalimov A, Ivashkin A, Kämpfer B, Kampert KH, Kardan B, Koenig I, Koenig W, Kornakov G, Kornas F, Kotte R, Kozela A, Kres I, Kuboś J, Kugler A, Kulesa P, Ladygin V, Lalik R, Lebedev A, Lebedev S, Linev S, Lopes L, Lorenz M, Lykasov G, Mahmoud T, Malige A, Markert J, Matulewicz T, Maurus S, Metag V, Michel J, Morozov S, Müntz C, Naumann L, Nowakowski K, Otto JH, Patel V, Pauly C, Pechenov V, Pechenova O, Petukhov O, Pfeifer D, Piasecki K, Pietraszko J, Prozorov A, Przygoda W, Pysz K, Ramstein B, Rathod N, Reshetin A, Ritman L, Rodriguez-Ramos P, Rost A, Salabura P, Scozzi F, Seck F, Selyuzhenkov I, Shabanov I, Singh US, Smyrski J, Spies S, Ströbele H, Stroth J, Stumm J, Svoboda O, Szala M, Tlusty P, Traxler M, Ungethüm C, Vazquez-Doce O, Wagner V, Weber A, Wendisch C, Wiebusch M, Wintz P, Wirth J, Zhilin A, Zumbruch P. Exploring time like tranistions in pp, πp and AA reactions with HADES. EPJ Web Conf 2020. [DOI: 10.1051/epjconf/202024101013] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Radiative transition of an excited baryon to a nucleon with emission of a virtual massive photon converting to dielectron pair (Dalitz decays) provides important information about baryon-photon coupling at low q2 in timelike region. A prominent enhancement in the respective electromagnetic transition Form Factors (etFF) at q2 near vector mesons ρ/ω poles has been predicted by various calculations reflecting strong baryon-vector meson couplings. The understanding of these couplings is also of primary importance for the interpretation of the emissivity of QCD matter studied in heavy ion collisions via dilepton emission. Dedicated measurements of baryon Dalitz decays in proton-proton and pion-proton scattering with HADES detector at GSI/FAIR are presented and discussed. The relevance of these studies for the interpretation of results obtained from heavy ion reactions is elucidated on the example of the HADES results.
Collapse
|
27
|
Chiesa-Estomba CM, Lechien JR, Radulesco T, Michel J, Sowerby LJ, Hopkins C, Saussez S. Patterns of smell recovery in 751 patients affected by the COVID-19 outbreak. Eur J Neurol 2020; 27:2318-2321. [PMID: 32677329 PMCID: PMC7405216 DOI: 10.1111/ene.14440] [Citation(s) in RCA: 76] [Impact Index Per Article: 19.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2020] [Accepted: 07/10/2020] [Indexed: 01/05/2023]
Abstract
BACKGROUND AND PURPOSE Post-viral olfactory dysfunction is well established and has been shown to be a key symptom of COVID-19 with more than 66% of European and US patients reporting some degree of loss of smell. Persistent olfactory dysfunction appears to be commonplace and will drive the demand for general practitioner, otolaryngology or neurology consultation in the next few months - evidence regarding recovery will be essential in counselling our patients. METHODS This was a prospective survey-based data collection and telemedicine follow-up. RESULTS In total, 751 patients completed the study, of whom 477 were females and 274 males. The mean age of the patients was 41 ± 13 years (range 18-60). There were 621 patients (83%) who subjectively reported a total loss of smell and 130 (17%) a partial loss. After a mean follow-up of 47 ± 7 days (range 30-71) from the first consultation, 277 (37%) patients still reported a persistent subjective loss of smell, 107 (14%) reported partial recovery and 367 (49%) reported complete recovery. The mean duration of the olfactory dysfunction was 10 ± 6 days (range 3-31) in those patients who completely recovered and 12 ± 8 days (range 7-35) in those patients who partially recovered. CONCLUSIONS According to our results, at this relatively early point in the pandemic, subjective patterns of recovery of olfactory dysfunction in COVID-19 patients are valuable for our patients, for hypothesis generation and for treatment development.
Collapse
Affiliation(s)
- C M Chiesa-Estomba
- COVID-19 Task Force of the Young Otolaryngologists of the International Federations of Oto-rhino-laryngological Societies (YO-IFOS), Paris, France.,Department of Otorhinolaryngology - Head and Neck Surgery, Hospital Universitario Donostia, San Sebastian, Spain
| | - J R Lechien
- COVID-19 Task Force of the Young Otolaryngologists of the International Federations of Oto-rhino-laryngological Societies (YO-IFOS), Paris, France.,Department of Otorhinolaryngology and Head and Neck Surgery, CHU de Bruxelles, CHU Saint-Pierre, School of Medicine, Université Libre de Bruxelles, Brussels, Belgium.,Department of Human Anatomy and Experimental Oncology, Faculty of Medicine, UMONS Research Institute for Health Sciences and Technology, University of Mons (UMons), Mons, Belgium.,Department of Otolaryngology - Head and Neck Surgery, Foch Hospital, School of Medicine, UFR Simone Veil, Université Versailles Saint-Quentin-en-Yvelines (Paris Saclay University), Paris, France
| | - T Radulesco
- COVID-19 Task Force of the Young Otolaryngologists of the International Federations of Oto-rhino-laryngological Societies (YO-IFOS), Paris, France.,Department of Oto-Rhino-Laryngology Head and Neck Surgery, Aix Marseille Univ, APHM, IUSTI, La Conception University Hospital, Marseille, France
| | - J Michel
- COVID-19 Task Force of the Young Otolaryngologists of the International Federations of Oto-rhino-laryngological Societies (YO-IFOS), Paris, France.,Department of Otolaryngology - Head and Neck Surgery, University of Western Ontario, London, Ontario, Canada
| | - L J Sowerby
- COVID-19 Task Force of the Young Otolaryngologists of the International Federations of Oto-rhino-laryngological Societies (YO-IFOS), Paris, France.,Department of Otolaryngology - Head and Neck Surgery, University of Western Ontario, London, Ontario, Canada
| | | | - S Saussez
- Department of Otorhinolaryngology - Head and Neck Surgery, Hospital Universitario Donostia, San Sebastian, Spain.,Department of Otolaryngology - Head and Neck Surgery, Foch Hospital, School of Medicine, UFR Simone Veil, Université Versailles Saint-Quentin-en-Yvelines (Paris Saclay University), Paris, France.,Department of Head and Neck Surgery, EpiCURA Hospital, Hornu, Belgium
| |
Collapse
|
28
|
Radulesco T, Lechien J, Chiesa-Estomba C, Sowerby L, Hopkins C, Saussez S, Michel J. Copper enhanced nasal saline irrigations: a safe potential treatment and protective factor for COVID-19 infection? RHINOL 2020. [DOI: 10.4193/rhinol/20.050] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022] Open
|
29
|
Radulesco T, Verillaud B, Béquignon E, Papon JF, Jankowski R, Le Taillandier De Gabory L, Dessi P, Coste A, Serrano E, Vergez S, Simon F, Couloigner V, Rumeau C, Michel J. COVID-19 and rhinology, from the consultation room to the operating theatre. Eur Ann Otorhinolaryngol Head Neck Dis 2020; 137:309-314. [PMID: 32387072 PMCID: PMC7190480 DOI: 10.1016/j.anorl.2020.04.013] [Citation(s) in RCA: 24] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
The purpose of this article is to give rhinologists advice on how to adapt their standard practice during the COVID-19 pandemic. The main goal of these recommendations is to protect healthcare workers against COVID-19 while continuing to provide emergency care so as to prevent loss of chance for patients. We reviewed our recommendations concerning consultations, medical prescriptions and surgical activity in rhinology.
Collapse
Affiliation(s)
- T Radulesco
- Department of otorhinolaryngology, head and neck surgery, La Conception university hospital, Assistance publique-Hôpitaux de Marseille, Marseille, France
| | - B Verillaud
- Department of otorhinolaryngology, head and neck surgery, Lariboisière university hospital, Assistance publique-Hôpitaux de Paris, Paris, France
| | - E Béquignon
- Department of otorhinolaryngology, head and neck surgery, Henri Mondor university hospitals, Créteil intercommunal hospital, Assistance publique-Hôpitaux de Paris, Créteil, France
| | - J-F Papon
- Department of otorhinolaryngology, head and neck surgery, Bicêtre university hospital, Assistance publique-Hôpitaux de Paris, Le Kremlin Bicêtre, France
| | - R Jankowski
- Department of otorhinolaryngology, head and neck surgery, Nancy university hospital, Nancy, France
| | - L Le Taillandier De Gabory
- Department of otorhinolaryngology, head and neck surgery, Pellegrin university hospital, Bordeaux, France
| | - P Dessi
- Department of otorhinolaryngology, head and neck surgery, La Conception university hospital, Assistance publique-Hôpitaux de Marseille, Marseille, France
| | - A Coste
- Department of otorhinolaryngology, head and neck surgery, Henri Mondor university hospitals, Créteil intercommunal hospital, Assistance publique-Hôpitaux de Paris, Créteil, France
| | - E Serrano
- Department of otorhinolaryngology, head and neck surgery, Larrey university hospital, Toulouse, France
| | - S Vergez
- Oncopole-1, university cancer Institute of Toulouse, Toulouse, France
| | - F Simon
- Paediatric ENT department, Necker-Enfants malades university hospital, Assistance publique-Hôpitaux de Paris, Paris, France
| | - V Couloigner
- Paediatric ENT department, Necker-Enfants malades university hospital, Assistance publique-Hôpitaux de Paris, Paris, France
| | - C Rumeau
- Department of otorhinolaryngology, head and neck surgery, Nancy university hospital, Nancy, France
| | - J Michel
- Department of otorhinolaryngology, head and neck surgery, La Conception university hospital, Assistance publique-Hôpitaux de Marseille, Marseille, France.
| | | | | |
Collapse
|
30
|
Jock A, Neunhoeffer F, Hofbeck M, Mustafi M, Schlensak C, Michel J. Capillary Refill Time versus Combination of Laser Doppler Flowmetry and White Light Spectrometry for Monitoring of Peripheral Microcirculation in Neonates and Infants following Palliation or Repair of Complex Congenital Heart Disease. Thorac Cardiovasc Surg 2020. [DOI: 10.1055/s-0040-1705562] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
31
|
Adamczewski-Musch J, Arnold O, Atomssa ET, Behnke C, Belounnas A, Belyaev A, Berger-Chen JC, Biernat J, Blanco A, Blume C, Böhmer M, Chernenko S, Chlad L, Chudoba P, Ciepał I, Deveaux C, Dittert D, Dreyer J, Epple E, Fabbietti L, Fateev O, Fonte P, Franco C, Friese J, Fröhlich I, Galatyuk T, Garzón JA, Gernhäuser R, Golubeva M, Greifenhagen R, Guber F, Gumberidze M, Harabasz S, Heinz T, Hennino T, Höhne C, Holzmann R, Ierusalimov A, Ivashkin A, Kämpfer B, Kardan B, Koenig I, Koenig W, Kolb BW, Korcyl G, Kornakov G, Kornas F, Kotte R, Kuboś J, Kugler A, Kunz T, Kurepin A, Kurilkin A, Kurilkin P, Ladygin V, Lalik R, Lapidus K, Lebedev A, Linev S, Lopes L, Lorenz M, Mahmoud T, Maier L, Malige A, Markert J, Maurus S, Metag V, Michel J, Mihaylov DM, Mikhaylov V, Morozov S, Müntz C, Münzer R, Naumann L, Nowakowski K, Parpottas Y, Pechenov V, Pechenova O, Petukhov O, Pietraszko J, Prozorov AP, Przygoda W, Ramstein B, Rathod N, Reshetin A, Rodriguez-Ramos P, Rost A, Sadovsky A, Salabura P, Scheib T, Schmidt-Sommerfeld K, Schuldes H, Schwab E, Scozzi F, Seck F, Sellheim P, Siebenson J, Silva L, Smyrski J, Spataro S, Spies S, Ströbele H, Stroth J, Strzempek P, Sturm C, Svoboda O, Szala M, Tlusty P, Traxler M, Tsertos H, Ungethüm C, Vázquez Doce O, Wagner V, Wendisch C, Wiebusch MG, Wirth J, Wójcik D, Zanevsky Y, Zumbruch P, Curceanu C, Piscicchia K, Scordo A. Strong Absorption of Hadrons with Hidden and Open Strangeness in Nuclear Matter. Phys Rev Lett 2019; 123:022002. [PMID: 31386541 DOI: 10.1103/physrevlett.123.022002] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/18/2018] [Revised: 04/29/2019] [Indexed: 06/10/2023]
Abstract
We present the first observation of K^{-} and ϕ absorption within nuclear matter by means of π^{-}-induced reactions on C and W targets at an incident beam momentum of 1.7 GeV/c studied with HADES at SIS18/GSI. The double ratio (K^{-}/K^{+})_{W}/(K^{-}/K^{+})_{C} is found to be 0.319±0.009(stat)_{-0.012}^{+0.014}(syst) indicating a larger absorption of K^{-} in heavier targets as compared to lighter ones. The measured ϕ/K^{-} ratios in π^{-}+C and π^{-}+W reactions within the HADES acceptance are found to be equal to 0.55±0.04(stat)_{-0.07}^{+0.06}(syst) and to 0.63±0.06(stat)_{-0.11}^{+0.11}(syst), respectively. The similar ratios measured in the two different reactions demonstrate for the first time experimentally that the dynamics of the ϕ meson in nuclear medium is strongly coupled to the K^{-} dynamics. The large difference in the ϕ production off C and W nuclei is discussed in terms of a strong ϕN in-medium coupling. These results are relevant for the description of heavy-ion collisions and the structure of neutron stars.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | - C Curceanu
- INFN, Laboratori Nazionali di Frascati, 00044 Frascati, Italy
| | - K Piscicchia
- INFN, Laboratori Nazionali di Frascati, 00044 Frascati, Italy
- CENTRO FERMI - Museo Storico della Fisica e Centro Studi e Ricerche "Enrico Fermi", 00184 Rome, Italy
| | - A Scordo
- INFN, Laboratori Nazionali di Frascati, 00044 Frascati, Italy
| |
Collapse
|
32
|
Radulesco T, Varoquaux A, Ranque S, Dessi P, Michel J, Cassagne C. Maxillary fungus balls due to Fusarium proliferatum. J Mycol Med 2019; 29:59-61. [PMID: 30738735 DOI: 10.1016/j.mycmed.2019.01.008] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/12/2018] [Revised: 01/23/2019] [Accepted: 01/24/2019] [Indexed: 12/01/2022]
Abstract
Fungus ball is the most common form of non-invasive fungal rhinosinusitis. Aspergillusfumigatus (between 44.8% and 75%) and Aspergillusflavus (14%) are the two most common species recovered. However, recent advances in mycological laboratory methods have enhanced the detection and identification of fungi within fungus balls. Fusarium species, sometimes recovered from other forms of fungal rhinosinusitis such as allergic fungal rhinosinusitis or acute invasive fungal rhinosinusitis, are poorly associated with sinonasal fungus ball. Here, we describe two further cases of a fungus ball due to Fusariumproliferatum and provide the first description of this fungal pathogen with a fungus ball of odontogenic origin. These case reports demonstrate that uncommon fungal species such as Fusarium spp. might be underestimated as agents of sinusal cavity fungus ball. Enhanced mycological detection and diagnostic techniques might give rise, in the near future, to the emergence of new or rare fungal species associated with this clinical entity.
Collapse
Affiliation(s)
- T Radulesco
- Department of Oto-Rhino-Laryngology and Head and Neck Surgery, La Conception University Hospital, Assistance publique-hôpitaux de Marseille, 13385 Marseille cedex, France; CNRS, IUSTI, Aix-Marseille Université, 13453 Marseille, France.
| | - A Varoquaux
- Department of Radiology, La Conception University Hospital, Assistance publique-hôpitaux de Marseille, 13385 Marseille cedex, France
| | - S Ranque
- SSA, IRD, IHU - Méditerranée Infection, VITROME, Aix-Marseille Université, AP-HM, 13005 Marseille, France
| | - P Dessi
- Department of Oto-Rhino-Laryngology and Head and Neck Surgery, La Conception University Hospital, Assistance publique-hôpitaux de Marseille, 13385 Marseille cedex, France
| | - J Michel
- Department of Oto-Rhino-Laryngology and Head and Neck Surgery, La Conception University Hospital, Assistance publique-hôpitaux de Marseille, 13385 Marseille cedex, France; CNRS, IUSTI, Aix-Marseille Université, 13453 Marseille, France
| | - C Cassagne
- SSA, IRD, IHU - Méditerranée Infection, VITROME, Aix-Marseille Université, AP-HM, 13005 Marseille, France
| |
Collapse
|
33
|
Patrick Mayr N, Michel J, Wiesner G, Rumpf PM. Supraglottic airway device use for transoesophageal echocardiography during left atrial appendage occlusion. Anaesthesia 2019; 74:405-406. [DOI: 10.1111/anae.14597] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
Affiliation(s)
| | - J. Michel
- Deutsches Herzzentrum München; Munich Germany
| | - G. Wiesner
- Deutsches Herzzentrum München; Munich Germany
| | - P. M. Rumpf
- Deutsches Herzzentrum München; Munich Germany
| |
Collapse
|
34
|
Ramstein B, Adamczewski-Musch J, Arnold O, Arnoldi-Meadows B, Belounnas A, Belyaev A, Biernat J, Blanco A, Blume C, Böhmer M, Bordalo P, Chlad L, Chudoba P, Ciepał I, Deveaux C, Dittert D, Dreyer J, Fabbietti L, Fateev O, Fonte P, Franco C, Friese J, Fröhlich I, Galatyuk T, Garzón JA, Gernhäuser R, Gillitzer A, Golubeva M, Greifenhagen R, Guber F, Gumberidze M, Harabasz S, Heinz T, Hennino T, Himmelreich M, Höhne C, Holzmann R, Ierusalimov A, Ivanov V, Ivashkin A, Kämpfer B, Kajetanowicz M, Kampert KH, Karavicheva T, Kardan B, Khomyakov V, Koenig I, Koenig W, Korcyl G, Kornakov G, Kornas F, Kotte R, Kozela A, Kuboś J, Kugler A, Kunz T, Kurepin A, Kurilkin P, Kushpil V, Ladygin V, Lalik R, Lebedev A, Linev S, Liu M, Lopes L, Lorenz M, Lykasov G, Mahmoud T, Malakhov A, Markert J, Maurus S, Metag V, Michel J, Mihaylov D, Mikhaylov V, Morozov S, Müntz C, Naumann L, Nowakowski K, Parpottas Y, Patel V, Pauly C, Pechenov V, Pechenova O, Pereira A, Petousis V, Petukhov O, Pfeifer D, Pietraszko J, Przygoda W, Pysz K, Ramos S, Reshetin A, Ritman L, Rodriguez-Ramos P, Rost A, Sadovsky A, Salabura P, Scheib T, Schuldes H, Schwab E, Scozzi F, Seck F, Sellheim P, Selyuzhenkov I, Silva L, Smyrski J, Sobiella M, Spataro S, Spies S, Ströbele H, Stroth J, Strzempek P, Svoboda O, Szala M, Taranenko A, Tlusty P, Traxler M, Troyan A, Tsertos H, Wagner V, Wendisch C, Wiebusch M, Wintz P, Wirth J, Włoch B, Zhilin A, Zinchenko A, Zumbruch P, Zuschke M. Time-Like Baryon Transitions studies with HADES. EPJ Web Conf 2019. [DOI: 10.1051/epjconf/201919901008] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
The HADES collaboration uses the e+e− production as a probe of the resonance matter produced in collisions at incident energies of 1-3.5 GeV/nucleon at GSI. Elementary reactions provide useful references for these studies and give information on resonance Dalitz decays (R→Ne+e−). Such processes are sensitive to the structure of time-like electromagnetic baryon transitions in a kinematic range where (off-shell) vector mesons play a crucial role. Results obtained in proton-proton reactions and in a commissioning pion-beam experiment are reported and prospects for future pion beam experiments and for first hyperon Dalitz decay measurements are described. The connection with the investigations of medium effects to be continued with HADES in the next years at SIS18 and SIS100 is also discussed.
Collapse
|
35
|
Adamczewski-Musch J, Akishin P, Becker K, Bendarouach J, Deveaux C, Dürr M, Eschke J, Förtsch J, Heep J, Höhne C, Ivanishchev D, Kampert K, Kochenda L, Kravtsov P, Kres I, Lebedev S, Lebedeva E, Linev S, Mahmoud T, Malaev M, Michel J, Miftakhov N, Niebur W, Otto J, Ovcharenko E, Patel V, Pauly C, Pfeifer D, Riabov Y, Roshchin E, Samsonov V, Tarasenkova O, Traxler M, Tyts D, Vznuzdaev M, Weber A, Zumbruch P. Event reconstruction of free-streaming data for the RICH detector in the CBM experiment. EPJ Web Conf 2019. [DOI: 10.1051/epjconf/201921401043] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
The Compressed Baryonic Matter (CBM) experiment is a dedicated heavy ion collision experiment at the FAIR facility. It will be one of the first HEP experiments which works in a triggerless mode: data received in the DAQ
from the detectors will not be associated with events by a hardware trigger anymore. All raw data within a giventime period will be collected continuously in containers, so-called time-slices. The task of the reconstruction algorithms is to create events out of this raw data stream. In this contribution, the optimization of the reconstruction software in the RICH detector to the free-streaming data flow is presented. The implementation of ring reconstruction algorithms which use time measurements of the hits as an additional parameter is discussed.
Collapse
|
36
|
Affiliation(s)
| | - J L Angel
- The University of Texas at Austin, Austin, Texas
| | - J Michel
- University of Geneva, Geneva, Valais
| |
Collapse
|
37
|
Radulesco T, Mancini J, Penicaud M, Dessi P, Michel J. Assessing normal values for the FACE-Q rhinoplasty module: An observational study. Clin Otolaryngol 2018; 43:1025-1030. [PMID: 29451357 DOI: 10.1111/coa.13086] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 02/12/2018] [Indexed: 11/28/2022]
Abstract
OBJECTIVES The goal of this study was to determine normal values for the FACE-Q rhinoplasty module. DESIGN A prospective monocentric observational cohort study. SETTING We tested FACE-Q Satisfaction with Nose and Satisfaction with Nostrils in two groups of patients, seeking or not a rhinoplasty. PARTICIPANTS One hundred and four patients were included in the study, fifty-two in each group. MAIN OUTCOME MEASUREMENTS Primary outcome was to identify possible cutting scores to establish normal values for each of the FQRM questionnaires. RESULTS Regarding the Satisfaction with Nose scale, there was a statistically significant difference between the two groups (P < .001). Area under the ROC curve was 0.964 (95% CI = 0.931-0.997). Forty-seven points was the value presenting the best Youden index (sensitivity = 96.2%, specificity = 86.5%). Regarding the Satisfaction with Nostrils scale, there was a statistically significant difference between the two groups (P < .001). Area under the ROC curve was 0.820 (95% CI = 0.741-0.899). Sixty-four points was the value presenting the best Youden index (sensitivity = 94.2%, specificity = 53.8%). CONCLUSION This is the first study to generate normative data for the FACE-Q rhinoplasty module. The findings presented here have important implications for future clinical care and research. The definition of a normal score can help practitioners to better analyse their patients and to support a therapeutic indication.
Collapse
Affiliation(s)
- T Radulesco
- Department of Oto-Rhino-Laryngology and Head and Neck Surgery, La Conception University Hospital, APHM, Marseille, France.,CNRS, IUSTI, Aix Marseille University, Marseille, France
| | - J Mancini
- Public Health Department (BIOSTIC), La Timone University Hospital, APHM, Marseille, France.,Inserm, IRD, Aix-Marseille University, Marseille, France
| | - M Penicaud
- Department of Oto-Rhino-Laryngology and Head and Neck Surgery, La Conception University Hospital, APHM, Marseille, France
| | - P Dessi
- Department of Oto-Rhino-Laryngology and Head and Neck Surgery, La Conception University Hospital, APHM, Marseille, France.,CNRS, IUSTI, Aix Marseille University, Marseille, France
| | - J Michel
- Department of Oto-Rhino-Laryngology and Head and Neck Surgery, La Conception University Hospital, APHM, Marseille, France.,CNRS, IUSTI, Aix Marseille University, Marseille, France
| |
Collapse
|
38
|
Michel J, Radulesco T, Graziani J, Penicaud M, Dessi P. Transpalpebral approach for frontal sinus diseases: A camouflaged technique. Clin Otolaryngol 2018; 43:1189-1191. [DOI: 10.1111/coa.13090] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 02/21/2018] [Indexed: 11/30/2022]
Affiliation(s)
- J. Michel
- Department of Oto‐Rhino‐Laryngology and Head and Neck Surgery Assistance Publique Hôpitaux de Marseille La Conception University Hospital Marseille France
- Aix Marseille University CNRS IUSTI UMR 7343 13453 Marseille France
| | - T. Radulesco
- Department of Oto‐Rhino‐Laryngology and Head and Neck Surgery Assistance Publique Hôpitaux de Marseille La Conception University Hospital Marseille France
- Aix Marseille University CNRS IUSTI UMR 7343 13453 Marseille France
| | - J. Graziani
- Department of Oto‐Rhino‐Laryngology and Head and Neck Surgery Assistance Publique Hôpitaux de Marseille La Conception University Hospital Marseille France
- Aix Marseille University CNRS IUSTI UMR 7343 13453 Marseille France
| | - M. Penicaud
- Department of Oto‐Rhino‐Laryngology and Head and Neck Surgery Assistance Publique Hôpitaux de Marseille La Conception University Hospital Marseille France
| | - P. Dessi
- Department of Oto‐Rhino‐Laryngology and Head and Neck Surgery Assistance Publique Hôpitaux de Marseille La Conception University Hospital Marseille France
- Aix Marseille University CNRS IUSTI UMR 7343 13453 Marseille France
| |
Collapse
|
39
|
Radulesco T, Penicaud M, Santini L, Thomassin JM, Dessi P, Michel J. Outcomes of septorhinoplasty: a new approach comparing functional and aesthetic results. Int J Oral Maxillofac Surg 2017; 47:175-179. [PMID: 28967532 DOI: 10.1016/j.ijom.2017.09.002] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2017] [Revised: 07/16/2017] [Accepted: 09/08/2017] [Indexed: 01/09/2023]
Abstract
The aim of this study was to compare objective and subjective functional results of septorhinoplasty with subjective aesthetic results. A prospective study was performed including global and subgroup analyses (primary versus secondary septorhinoplasty). Three instruments were used to evaluate pre- and postoperative results: rhinomanometry for the objective functional analysis, the Nasal Symptom Obstruction Evaluation (NOSE) scale for the subjective functional analysis, and the Rhinoplasty Outcome Evaluation (ROE) scale for the subjective aesthetic analysis. A septorhinoplasty was performed in all cases. Thirty-five patients were included (22 female), of whom 74% underwent primary septorhinoplasty. The correlation between rhinomanometry, NOSE and ROE scores was analysed. Mean resistance of the two nasal cavities was 4.9 (standard deviation (SD) 8.35) sPa/ml before surgery and 0.8 (SD 0.7) sPa/ml after surgery. NOSE and ROE scores were, respectively, 72.5/100 (SD 21.7) and 7.5/24 (SD 11.3) before surgery and 22/100 (SD 20.6) and 18/24 (SD 17.3) after surgery. Patients complaining of postoperative nasal obstruction had a worse aesthetic evaluation. Correction of the functional disease appears to be as important as aesthetic correction. This study comparing functional and aesthetic results after septorhinoplasty could provide a basis for future studies.
Collapse
Affiliation(s)
- T Radulesco
- Department of Otorhinolaryngology and Head and Neck Surgery, Assistance Publique Hôpitaux de Marseille, La Conception University Hospital, Marseille, France; Aix-Marseille Univ, Marseille, France.
| | - M Penicaud
- Department of Otorhinolaryngology and Head and Neck Surgery, Assistance Publique Hôpitaux de Marseille, La Conception University Hospital, Marseille, France
| | - L Santini
- Department of Otorhinolaryngology and Head and Neck Surgery, Assistance Publique Hôpitaux de Marseille, La Conception University Hospital, Marseille, France
| | - J-M Thomassin
- Department of Otorhinolaryngology and Head and Neck Surgery, Assistance Publique Hôpitaux de Marseille, La Conception University Hospital, Marseille, France; Aix-Marseille Univ, Marseille, France
| | - P Dessi
- Department of Otorhinolaryngology and Head and Neck Surgery, Assistance Publique Hôpitaux de Marseille, La Conception University Hospital, Marseille, France; Aix-Marseille Univ, Marseille, France
| | - J Michel
- Department of Otorhinolaryngology and Head and Neck Surgery, Assistance Publique Hôpitaux de Marseille, La Conception University Hospital, Marseille, France; Aix-Marseille Univ, Marseille, France
| |
Collapse
|
40
|
Raskin A, Ruquet M, Weiss-Pelletier L, Mancini J, Boulogne O, Michel J, Fakhry N, Foletti JM, Chossegros C, Giorgi R. Upper aerodigestive tract cancer and oral health status before radiotherapy: A cross-sectional study of 154 patients. J Stomatol Oral Maxillofac Surg 2017; 119:2-7. [PMID: 28911982 DOI: 10.1016/j.jormas.2017.09.004] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/11/2017] [Accepted: 09/04/2017] [Indexed: 11/26/2022]
Abstract
OBJECTIVES We aimed to determine primarily the oral health status of patients with upper aerodigestive tract cancer before radiotherapy, and secondarily the prevalence of risk factors for poor oral status. METHODS A cross-sectional study was conducted in Marseille University hospital. Assessment criteria were the Decay, Missing and Filled (DMF) Index and periodontal status. RESULTS One hundred and fifty-four patients, mean age 60.9years, were included. The most common sites of primary tumors were the larynx (28.6%) and oral cavity (26.6%). Current or past smokers accounted for 80.5% of patients and 67% were alcohol abusers. Most patients (83.8%) did not have xerostomia. They ate three meals a day (61%), with sugar consumption in 40%. The median number of daily tooth brushings was 2, with a manual toothbrush (81.2%). Few patients used dental floss or interproximal brushes. Individual DMF index was 17.6 (D=2.3, M=9.3, F=6.0) and was higher in patients with xerostomia and alcohol abusers (P=0.01). Osseous level was 62.3% and 57.8% of patients had osseous infections, which were more common with poor hygiene (P=0.04). Most patients (85.7%) had periodontal disease, but incidence did not significantly differ according to risk factors. DISCUSSION The DMF index was higher in presence of periodontal disease and osseous infections. Alcohol and xerostomia were associated with a high individual DMF index and osseous infections were more frequent in patients with poor hygiene. Patients with upper aerodigestive tract cancer are at high risk of osteoradionecrosis if they do not receive dental treatment before radiotherapy.
Collapse
Affiliation(s)
- A Raskin
- Faculté d'odontologie, Aix-Marseille université, 27, boulevard Jean-Moulin, 13355 Marseille cedex 5, France; Pôle d'odontologie, UF des soins spécifiques, hôpital de la Timone, Assistance publique-Hôpitaux de Marseille, 264, rue Saint-Pierre, 13385 Marseille cedex 5, France; EFS CNRS, faculté de médecine, UMR 7268 ADES, Aix-Marseille université, 51, boulevard Pierre-Dramard, 13944 Marseille cedex 15, France.
| | - M Ruquet
- Faculté d'odontologie, Aix-Marseille université, 27, boulevard Jean-Moulin, 13355 Marseille cedex 5, France; Pôle d'odontologie, UF des soins spécifiques, hôpital de la Timone, Assistance publique-Hôpitaux de Marseille, 264, rue Saint-Pierre, 13385 Marseille cedex 5, France; EFS CNRS, faculté de médecine, UMR 7268 ADES, Aix-Marseille université, 51, boulevard Pierre-Dramard, 13944 Marseille cedex 15, France
| | - L Weiss-Pelletier
- Pôle d'odontologie, UF des soins spécifiques, hôpital de la Timone, Assistance publique-Hôpitaux de Marseille, 264, rue Saint-Pierre, 13385 Marseille cedex 5, France
| | - J Mancini
- Faculté de médecine, Aix-Marseille université, 27, boulevard Jean-Moulin, 13355 Marseille cedex 5, France; Pôle de santé publique BIOSTIC, service biostatistique et technologies de l'information et de la communication, hôpital de la Timone, Assistance publique-Hôpitaux de Marseille, 264, rue Saint-Pierre, 13385 Marseille cedex 5, France; SESSTIM sciences économiques et sociales de la santé et traitement de l'information médicale, UMR 912 Inserm/IRD/Aix-Marseille université, faculté de médecine, 27, boulevard Jean-Moulin, 13385 Marseille cedex 5, France
| | - O Boulogne
- Faculté de médecine, Aix-Marseille université, 27, boulevard Jean-Moulin, 13355 Marseille cedex 5, France; Pôle de santé publique BIOSTIC, service biostatistique et technologies de l'information et de la communication, hôpital de la Timone, Assistance publique-Hôpitaux de Marseille, 264, rue Saint-Pierre, 13385 Marseille cedex 5, France; SESSTIM sciences économiques et sociales de la santé et traitement de l'information médicale, UMR 912 Inserm/IRD/Aix-Marseille université, faculté de médecine, 27, boulevard Jean-Moulin, 13385 Marseille cedex 5, France
| | - J Michel
- EFS CNRS, faculté de médecine, UMR 7268 ADES, Aix-Marseille université, 51, boulevard Pierre-Dramard, 13944 Marseille cedex 15, France; Faculté de médecine, Aix-Marseille université, 27, boulevard Jean-Moulin, 13355 Marseille cedex 5, France; Pôle PROMO, service ORL et chirurgie cervico-faciale, hôpital de la conception, Assistance publique-Hôpitaux de Marseille, 147, boulevard Baille, 13005 Marseille, France
| | - N Fakhry
- Faculté de médecine, Aix-Marseille université, 27, boulevard Jean-Moulin, 13355 Marseille cedex 5, France; Pôle PROMO, service ORL et chirurgie cervico-faciale, hôpital de la conception, Assistance publique-Hôpitaux de Marseille, 147, boulevard Baille, 13005 Marseille, France
| | - J M Foletti
- Faculté de médecine, Aix-Marseille université, 27, boulevard Jean-Moulin, 13355 Marseille cedex 5, France
| | - C Chossegros
- Faculté de médecine, Aix-Marseille université, 27, boulevard Jean-Moulin, 13355 Marseille cedex 5, France; Pôle PROMO, service ORL et chirurgie cervico-faciale, hôpital de la conception, Assistance publique-Hôpitaux de Marseille, 147, boulevard Baille, 13005 Marseille, France
| | - R Giorgi
- Faculté de médecine, Aix-Marseille université, 27, boulevard Jean-Moulin, 13355 Marseille cedex 5, France; Pôle de santé publique BIOSTIC, service biostatistique et technologies de l'information et de la communication, hôpital de la Timone, Assistance publique-Hôpitaux de Marseille, 264, rue Saint-Pierre, 13385 Marseille cedex 5, France; SESSTIM sciences économiques et sociales de la santé et traitement de l'information médicale, UMR 912 Inserm/IRD/Aix-Marseille université, faculté de médecine, 27, boulevard Jean-Moulin, 13385 Marseille cedex 5, France
| |
Collapse
|
41
|
|
42
|
Colleran R, Michel J, Giacoppo D, Cassese S, Joner M, Kastrati A, Byrne R. 2201Comparative efficacy and safety of novel biodegradable polymer sirolimus-eluting stents versus permanent polymer everolimus-eluting stents at 5-year follow-up. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx502.2201] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
43
|
Brendel LC, Dobler F, Hessling G, Michel J, Braun SL, Steinsiek AL, Groha P, Eckl R, Deisenhofer I, Hyseni A, Roest M, Ott I, Steppich B. The anticoagulant effect of heparin during radiofrequency ablation (RFA) in patients taking apixaban or rivaroxaban. J Interv Card Electrophysiol 2017; 49:237-244. [PMID: 28735423 DOI: 10.1007/s10840-017-0274-2] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/10/2016] [Accepted: 07/10/2017] [Indexed: 01/09/2023]
Abstract
PURPOSE Measuring the anticoagulant effect of heparin during radiofrequency ablation (RFA) in patients taking apixaban and rivaroxaban is challenging, since the activated coagulation time (ACT) does not seem to reflect the true anticoagulant activity of these drugs. We therefore evaluated coagulation properties of apixaban and rivaroxaban during RFA by different coagulation assays to better monitor periprocedural hemostasis. METHODS The study included 90 patients (61 ± 12 years) with atrial fibrillation who underwent RFA procedures. Patients received 20 mg rivaroxaban (n = 73) once or 5 mg apixaban (n = 17) twice daily 4 weeks prior to the procedure. During RFA, unfractionated heparin i.v. was given to maintain an ACT of 250-300 s. Blood samples were taken before and 10, 60, and 360 min after heparin administration. RESULTS Heparin displayed a lower anti-Xa activity in rivaroxaban-treated patients compared to apixaban-treated patients. In contrast, D-dimer and prothrombin fragment F1+2 plasma levels indicated a higher activation of the coagulation cascade in apixaban/heparin than in rivaroxaban/heparin patients. This discordant coagulative state measured in vitro had no clinical impact in terms of bleeding or thromboembolic complications. CONCLUSION We found different biochemical responses to rivaroxaban/heparin and apixaban/heparin during RFA. Precaution is necessary when monitoring periprocedural hemostasis in DOAC patients to avoid mismanagement.
Collapse
Affiliation(s)
- L C Brendel
- Deutsches Herzzentrum der Technischen Universität München, Lazarettstr. 36, 80636, Munich, Germany
| | - F Dobler
- Deutsches Herzzentrum der Technischen Universität München, Lazarettstr. 36, 80636, Munich, Germany
| | - G Hessling
- Deutsches Herzzentrum der Technischen Universität München, Lazarettstr. 36, 80636, Munich, Germany
| | - J Michel
- Deutsches Herzzentrum der Technischen Universität München, Lazarettstr. 36, 80636, Munich, Germany
| | - S L Braun
- Deutsches Herzzentrum der Technischen Universität München, Lazarettstr. 36, 80636, Munich, Germany
| | - A L Steinsiek
- Deutsches Herzzentrum der Technischen Universität München, Lazarettstr. 36, 80636, Munich, Germany
| | - P Groha
- Deutsches Herzzentrum der Technischen Universität München, Lazarettstr. 36, 80636, Munich, Germany
| | - R Eckl
- Deutsches Herzzentrum der Technischen Universität München, Lazarettstr. 36, 80636, Munich, Germany
| | - I Deisenhofer
- Deutsches Herzzentrum der Technischen Universität München, Lazarettstr. 36, 80636, Munich, Germany
| | - A Hyseni
- Department of Clinical Chemistry and Haematology, University Medical Center Utrecht, Utrecht, The Netherlands
| | - M Roest
- Department of Clinical Chemistry and Haematology, University Medical Center Utrecht, Utrecht, The Netherlands
| | - I Ott
- Deutsches Herzzentrum der Technischen Universität München, Lazarettstr. 36, 80636, Munich, Germany
| | - B Steppich
- Deutsches Herzzentrum der Technischen Universität München, Lazarettstr. 36, 80636, Munich, Germany.
| |
Collapse
|
44
|
Radulesco T, Penicaud M, Dessi P, Michel J. Endoscopic surgery for sinonasal tumors: The transcribriform approach. J Stomatol Oral Maxillofac Surg 2017; 118:248-250. [PMID: 28689974 DOI: 10.1016/j.jormas.2017.06.015] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/07/2017] [Accepted: 06/09/2017] [Indexed: 10/19/2022]
Abstract
Over the past 10 to 20 years, endoscopic endonasal surgery has become for many teams the preferred treatment for sinonasal tumors. Technical advances in the field of surgical instrumentation (good visualization, hemostasis…) and the progress of imaging guidance (to avoid neurovascular complication) has made those procedures simpler and safer. Nevertheless, endonasal endoscopic procedures require a trained surgical team of ENT specialist and neurosurgeon. Endoscopic endonasal surgery has been reported to be feasible for all types of sinonasal tumors whether benign tumors such as inverted papillomas, or malignant tumors. In this paper, we mostly focus on the principles underlying the transcribriform approach, which is dedicated to the surgery of CSF leaks, encephaloceles/meningoceles, access to benign intracranial tumors such as olfactory groove meningiomas, and the resection of sinonasal malignancies with skull base invasion such as olfactory neuroblastomas.
Collapse
Affiliation(s)
- T Radulesco
- IUSTI, UMR 7343 CNRS AMU, 5 rue Enrico-Fermi, 13453 Marseille cedex 13, France
| | - M Penicaud
- Department of Otolaryngology, Head and Neck Surgery, La Conception University Hospital Center, 147, boulevard Baille, 13385 Marseille cedex, France
| | - P Dessi
- Department of Otolaryngology, Head and Neck Surgery, La Conception University Hospital Center, 147, boulevard Baille, 13385 Marseille cedex, France; Departement of Anthropolgy, ADES UMR 7268 CNRS Aix Marseille University EFS, faculté de médecine Nord, 51, boulevard Pierre-Dramart, 13015 Marseille, France
| | - J Michel
- Department of Otolaryngology, Head and Neck Surgery, La Conception University Hospital Center, 147, boulevard Baille, 13385 Marseille cedex, France; IUSTI, UMR 7343 CNRS AMU, 5 rue Enrico-Fermi, 13453 Marseille cedex 13, France.
| |
Collapse
|
45
|
Affiliation(s)
- J Michel
- Department of Oto-Rhino-Laryngology and Head and Neck Surgery, Assistance Publique, Hôpitaux de Marseille, La Conception University Hospital, Marseille Cedex, France.,Aix-Marseille University, Marseille Cedex, France
| | - T Radulesco
- Department of Oto-Rhino-Laryngology and Head and Neck Surgery, Assistance Publique, Hôpitaux de Marseille, La Conception University Hospital, Marseille Cedex, France.,Aix-Marseille University, Marseille Cedex, France
| | - M Penicaud
- Department of Oto-Rhino-Laryngology and Head and Neck Surgery, Assistance Publique, Hôpitaux de Marseille, La Conception University Hospital, Marseille Cedex, France.,Aix-Marseille University, Marseille Cedex, France
| | - P Dessi
- Department of Oto-Rhino-Laryngology and Head and Neck Surgery, Assistance Publique, Hôpitaux de Marseille, La Conception University Hospital, Marseille Cedex, France.,Aix-Marseille University, Marseille Cedex, France
| |
Collapse
|
46
|
Mortuaire G, Michel J, Papon JF, Malard O, Ebbo D, Crampette L, Jankowski R, Coste A, Serrano E. Specific immunotherapy in allergic rhinitis. Eur Ann Otorhinolaryngol Head Neck Dis 2017; 134:253-258. [PMID: 28684084 DOI: 10.1016/j.anorl.2017.06.005] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Allergic rhinitis is a common condition, with significant impact on quality of life depending on severity and quality of control. Allergen-specific immunotherapy (allergen-SIT) is the only known treatment able to alter the natural course of allergic rhinitis. Although well known to allergologists, it has yet to be fully adopted by the ENT community. This review, based on the most recent meta-analyses and clinical studies, shows that SIT significantly reduces symptoms and medication requirements (nasal corticosteroids, H1-antihistamines) in allergic rhinitis. It can reduce the risk of progression to asthma and, if initiated early enough, of developing new sensitizations. Immunobiological analysis shows an altered inflammatory profile following SIT, with immune tolerance involving T-regulatory lymphocyte induction and IgG production. Sublingual SIT with drops is as effective as subcutaneous SIT and is simpler to use, with less anaphylactic risk. Standardization of trial protocols in terms of treatment response assessment and side effect grading is recommended to improve comparative studies. Sublingual SIT with tablets has recently been introduced, providing a good opportunity for ENT practitioners to adopt the SIT approach in rhinitis triggered by allergy to pollens and, in the near future, to house dust mites.
Collapse
Affiliation(s)
- G Mortuaire
- Inserm U995, service d'ORL et de chirurgie cervicofaciale, Lille Inflammation Research International Center, université de Lille, hôpital Huriez, CHU de Lille, 59000 Lille, France.
| | - J Michel
- Service d'ORL et de chirurgie cervicofaciale, CHU Hôpital La Conception, AP-HM, 147, boulevard Baille, 13005 Marseille, France
| | - J F Papon
- Service d'ORL et de chirurgie cervicofaciale, Bicêtre, AP-HP, 78, rue du Général-Leclerc, 94270 Le Kremlin-Bicêtre, France
| | - O Malard
- Service d'ORL et de chirurgie cervicofaciale, CHU de Nantes, 44000 Nantes, France
| | - D Ebbo
- Groupe hospitalier Paris-Saint-Joseph, 185, rue Raymond-Losserand, 75014 Paris, France
| | - L Crampette
- Service d'ORL et de chirurgie cervicofaciale, CHU de Montpellier, 34090 Montpellier, France
| | - R Jankowski
- Service d'ORL et de chirurgie cervicofaciale, CHU Nancy, 54500 Vandœuvre-lès-Nancy, France
| | - A Coste
- Service d'ORL et de chirurgie cervicofaciale, CHU de Créteil, 94000 Créteil, France
| | - E Serrano
- Service d'ORL et de chirurgie cervicofaciale, CHU de Toulouse, 31059 Toulouse, France
| |
Collapse
|
47
|
|
48
|
Bequignon E, Vérillaud B, Robard L, Michel J, Prulière Escabasse V, Crampette L, Malard O, Malard O, Crampette L, Achache M, Alaoui Lamrani Y, Ardillon L, Babin E, Bal Dit Sollier C, Bequignon E, Borsik M, Castillo L, Coste A, Debry C, Dessi P, Drouet L, Dufour X, Dupuis-Girod S, Faure F, Gallet P, Guldman R, Houdart E, Jankowski R, Jegoux F, Leble S, Michel J, Mortuaire G, Mouchon E, Page C, Prulière Escabasse V, Robard L, Roux A, Saint Maurice J, Sarlon G, Strunski V, Trevillot V, Vérillaud B, Vironneau P. Guidelines of the French Society of Otorhinolaryngology (SFORL). First-line treatment of epistaxis in adults. Eur Ann Otorhinolaryngol Head Neck Dis 2017; 134:185-189. [DOI: 10.1016/j.anorl.2016.09.008] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
49
|
Escabasse V, Bequignon E, Vérillaud B, Robard L, Michel J, Malard O, Crampette L, Malard O, Crampette L, Achache M, Alaoui Lamrani M, Ardillon L, Babin E, Bal Dit Sollier C, Bequignon E, Borsik M, Castillo L, Coste A, Debry C, Dessi P, Drouet L, Dufour X, Dupuis-Girod S, Faure F, Gallet P, Guldman R, Houdart E, Jankowski R, Jegoux F, Leble S, Michel J, Mortuaire G, Mouchon E, Page C, Pruliere Escabasse V, Robard L, Roux A, Saint Maurice J, Sarlon G, Strunski V, Trevillot V, Verillaud B, Vironneau P. Guidelines of the French Society of Otorhinolaryngology (SFORL). Managing epistaxis under coagulation disorder due to antithrombotic therapy. Eur Ann Otorhinolaryngol Head Neck Dis 2017; 134:195-199. [DOI: 10.1016/j.anorl.2016.10.001] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
50
|
Radulesco T, Penicaud M, Santini L, Thomassin JM, Dessi P, Michel J. The MiRa scale, a new standardised scale for evaluating nasal deformities before and after septorhinoplasty: A prospective study comparing patient satisfaction and the surgeon's assessment. Clin Otolaryngol 2017; 42:1350-1357. [PMID: 28374943 DOI: 10.1111/coa.12885] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/30/2017] [Indexed: 01/09/2023]
Abstract
OBJECTIVES The objective was to assess the reliability of a new standardised scale for evaluating nasal anomalies in order to compare the surgeon's assessment and patient satisfaction. DESIGN Monocentric prospective cohort study. SETTINGS First, we validated the reliability of the MiRa scale; then, we compared the surgeon's assessment and patient satisfaction. PARTICIPANTS Fifty-two patients underwent septorhinoplasty surgery and gave their written consent before inclusion. MAIN OUTCOME MEASUREMENTS Primary outcome measurement was to validate the reliability of the MiRa scale: two observers analysed all records twice. Intra-observer reproducibility and interobserver reproducibility were evaluated using the intraclass correlation coefficient (ICC). Secondary outcome measurement was to compare the surgeon's assessment and patient satisfaction: MiRa and ROE (Rhinoplasty Outcome Evaluation) scores were established for each patient prior to and 6 months after surgery. RESULTS Using the MiRa scale, ICC for intra- and interobserver reproducibility was, respectively, 95.4% and 96%, showing no statistical difference (P=.70, P=.45). Good correlation scores were, respectively, 93% and 92%. Mean ROE scores were 7.1/24 (SD=11.3) before and 19.3/24 (SD=17.3) after surgery (P<.05). We found an increase in MiRa and ROE scores of +19.75% and +51.25% (P<.05), respectively. The average postoperative ROE score in the primary septorhinoplasty group was 20.4 (SD=14.4) and 17.2 (SD=23.1) in the secondary septorhinoplasty group (P<.05). CONCLUSION MiRa scale is a reliable, standardised tool to evaluate surgical outcome in septorhinoplasty surgery. It provides an objective and reproducible score. The surgeon's assessment was more critical than patient satisfaction. Patient satisfaction is more difficult to achieve in cases involving a secondary septorhinoplasty.
Collapse
Affiliation(s)
- T Radulesco
- Department of Oto-Rhino-Laryngology and Head and Neck Surgery, Assistance Publique Hôpitaux de Marseille, La Conception University Hospital, Marseille Cedex, France.,Aix-Marseille University, Marseille Cedex, France
| | - M Penicaud
- Department of Oto-Rhino-Laryngology and Head and Neck Surgery, Assistance Publique Hôpitaux de Marseille, La Conception University Hospital, Marseille Cedex, France
| | - L Santini
- Department of Oto-Rhino-Laryngology and Head and Neck Surgery, Assistance Publique Hôpitaux de Marseille, La Conception University Hospital, Marseille Cedex, France.,Aix-Marseille University, Marseille Cedex, France
| | - J-M Thomassin
- Department of Oto-Rhino-Laryngology and Head and Neck Surgery, Assistance Publique Hôpitaux de Marseille, La Conception University Hospital, Marseille Cedex, France.,Aix-Marseille University, Marseille Cedex, France
| | - P Dessi
- Department of Oto-Rhino-Laryngology and Head and Neck Surgery, Assistance Publique Hôpitaux de Marseille, La Conception University Hospital, Marseille Cedex, France.,Aix-Marseille University, Marseille Cedex, France
| | - J Michel
- Department of Oto-Rhino-Laryngology and Head and Neck Surgery, Assistance Publique Hôpitaux de Marseille, La Conception University Hospital, Marseille Cedex, France.,Aix-Marseille University, Marseille Cedex, France
| |
Collapse
|